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OUTLINE AND OBJECTIVES 
 
 
Co-extrusion is defined as the simultaneous hot-melt extrusion of two or more materials 
through the same die, creating a multilayered extrudate. The technique allows to combine 
the desirable properties of multiple materials into a single structure with enhanced 
performance characteristics. It is an innovative technology for the continuous production of 
multilayered dosage forms that offers numerous advantages over traditional pharmaceutical 
processing techniques. Co-extrusion provides great potential for the production of fixed-
dose combination products, which are gaining importance in pharmaceutical industry due to 
their improved patient convenience and adherence and better clinical outcomes. The 
objective of this work was to examine the possibilities of hot-melt co-extrusion for the 
production of multilayer oral dosage forms, providing different release profiles for each of 
the drugs incorporated in the core and coat of the co-extruded form. 
 
In the Introduction hot-melt co-extrusion is reviewed as a manufacturing technology, 
illustrating its advantages and shortcomings. An overview of the equipment required for co-
extrusion is provided, including the downstream solutions to process a final dosage form. 
Medical and pharmaceutical applications of the technology and proper material selection 
are pointed out. The increasing importance of fixed-dose combinations in the 
pharmaceutical industry is discussed.      
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In Chapter 1, hot-melt co-extrusion is evaluated as a technique for the production of fixed-
dose combination mini-matrices, using an ethylcellulose core to control the release of 
metoprolol tartrate and a polyethylene oxide-based coat to obtain immediate release of 
hydrochlorothiazide. The in vitro performance of the different formulations was assessed. 
The physicochemical state of the drugs in the formulations was characterized using 
modulated differential scanning calorimetry (MDSC), X-ray diffraction (XRD) and Raman 
spectroscopy. Furthermore, the physical stability of the co-extruded mini-matrices was 
monitored during 6 months storage at 25 °C/60 %RH and 40 °C/75 %RH. The bioavailability 
of the different formulations was evaluated after oral administration to dogs and compared 
to that of a commercially available fixed-dose combination product. Additionally a 
mathematical model considering the controlled release of metoprolol tartrate from the 
dosage form and the in vivo fate of the drug was developed and used to predict the resulting 
drug plasma profiles, based on the in vitro results and in vivo parameters reported in 
literature. 
 
In Chapter 2, calendering is used as a downstream technique to shape the co-extruded fixed-
dose formulation in a continuous way into its final form. Co-extrudates with a metoprolol 
tartrate-loaded sustained-release core and a hydrochlorothiazide-loaded immediate-release 
coat were immediately shaped into a monolithic drug delivery system via calendering, using 
chilled rolls with tablet-shaped cavities. The dosage forms produced were evaluated for in 
vitro drug release, coat thickness, uniformity and pore structure. The impact of the 
calendering step on the physical state of the drugs in the formulations was characterized 
using MDSC and XRD. 
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The aim of the experiments performed in Chapter 3 was to design a fixed-dose combination 
dosage form which provides sustained release for both the freely water-soluble metformin 
HCl and the poorly soluble gliclazide, two anti-diabetic compounds used to treat diabetes 
mellitus, using co-extrusion as manufacturing technique. Developing a matrix formulation 
that sustained metformin release was challenging, given that its high dose requires a high 
drug load in the formulation and that the drug is freely soluble. Both active pharmaceutical 
ingredients (API’s) were formulated in a single dosage form composed of two separate 
layers, each demonstrating adequate properties for the incorporated API. In vitro release 
and physicochemical state of the drugs incorporated was characterized.  
 
In Chapter 4, hot-melt co-extrusion is used as a processing technique to manufacture a 
fixed-dose combination product providing enteric protection to naproxen incorporated in 
the core and immediate release to esomeprazole magnesium embedded in the coat. Both 
core and coat were first independently developed. Several enteric polymers (Eudragit® L100-
55, HPMC-AS-LF and HPMCP-HP-50) were tested as core matrix former in combination with 
naproxen. The physicochemical state of the drug in the extrudates was determined and a 
stability study was performed. Intermolecular interactions between naproxen and polymer 
were identified using attenuated total reflectance Fourier transform infrared (ATR FT-IR) 
spectroscopy. Since gastro-protective co-therapy using a proton pump inhibitor is 
recommended to decrease the incidence of non-steroidal anti-inflammatory drug (NSAID)-
related adverse events, esomeprazole magnesium was formulated in a separate non-enteric 
polymer layer providing immediate drug release. Different polymers were tested and their 
influence on release and physicochemical state characteristics was monitored. Finally it was 
evaluated if co-extrusion of a core/coat dosage form allowed to formulate the two 
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chemically incompatible API’s in a fixed-dose combination that offered the desired release 
profile for both API’s. 
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ABSTRACT 
 
In this chapter co-extrusion is reviewed as an innovative continuous production technology 
for fixed-dose combination drug products. The equipment needed for co-extrusion of 
pharmaceutical dosage forms is summarized. Because the geometrical design of the die 
dictates the shape of the final product, different die types are discussed. As a major 
challenge is shaping of the co-extruded formulation into its final form via a continuous 
process, an overview of downstream solutions for processing co-extrudates into drug 
products is provided. Important requirements for material selection are pointed out. 
Examples of medical and pharmaceutical applications are presented. Co-extrusion offers 
great potential for the continuous production of fixed-dose combination products which are 
gaining importance in pharmaceutical industry, since combination therapy is increasingly 
recognized as a major advantage, not only for life cycle management of drugs but also for 
therapeutic reasons. Although co-extrusion is a very promising formulation technique, there 
are still some barriers to the implementation of co-extrusion in the pharmaceutical industry. 
The optimization of downstream processing remains a point of attention.  
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INTRODUCTION 
HOT-MELT CO-EXTRUSION:  
PROCESS AND APPLICATIONS 
 
 
HOT-MELT CO-EXTRUSION 
 
Hot-melt extrusion (HME), a processing technique widely used in plastic and food industry, is 
defined as the pumping of raw materials through a die into a product of uniform shape by 
means of a rotating screw and under elevated temperature [1]. HME is a viable method for 
the production of granules, pellets, spheres, tablets, capsules, implants and transdermal, 
transmucosal or transungual films [2, 3]. This technique has found its way into the 
pharmaceutical industry because of its advantages over conventional techniques, such as the 
possibility to improve drug solubility, to sustain drug release and to mask bitter taste of an 
active pharmaceutical ingredient (API). Other major benefits of the technique are that there 
are no requirements for the compressibility of the formulation, the continuity of the process 
(requiring fewer processing steps) and the low environmental impact (given the solvent-free 
nature of the process) [1-5]. Continuous manufacturing also provides specific advantages 
compared to a batch-wise approach: a shorter development time because of a more 
straightforward scale-up, easier automation of the production line, improved quality and 
less product variability (via in-line quality control), a faster product release, lower product 
rejection rates [6]. The reduction in production costs when shifting to HME as a continuous 
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processing technique may however be nullified by the investment in novel equipment and 
by the need for experienced line operators, given the increased level of process complexity. 
HME is now being used in pharmaceutical industry for the production of drug delivery 
systems like transdermal patches and solid dosage forms. The number of HME patents 
issued worldwide also importantly increased since the early 1980s [3]. 
When hot-melt extrusion of two or more materials is performed through the same die, to 
create a multiple layer extrudate, the process is defined as co-extrusion [7]. In this way the 
properties of multiple materials are combined into a single structure. The technique has 
already been used for several decades in plastics and food industry to produce a broad range 
of applications, e.g. pipes, wires, packaging material and filled snacks. Co-extrusion has 
extensively been used to produce medical devices, but is relatively new for pharmaceutical 
applications. However, several applications of co-extrusion for oral drug delivery are 
possible: (a) combining drugs with different release profiles since drug release can be 
individually modulated, depending on the characteristics of the layer in which the drug is 
incorporated, (b) producing a solid dosage form which provides dual release of a single drug, 
(c) simultaneous administration of non-compatible drugs. 
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PROCESS AND EQUIPMENT 
 
Co-extrusion implies extruding two or more materials through a single die. The materials for 
each of the layers (API, polymer, plasticizer and/or other additives) are premixed or 
separately fed into an extruder. In each heated extruder barrel the material is softened, 
mixed and finally extruded through the die, where the different melt streams are combined 
into the final co-extrudate. The co-extrudate is then shaped, cooled and further processed. 
Throughout the entire process several important process parameters need to be controlled. 
Process analytical technology (PAT) can be used for in-line control of the product quality.  
The co-extrusion equipment that was traditionally designed for the plastics industry needed 
to be adapted to meet regulatory requirements for pharmaceutical use. All product contact 
parts need to be Good Manufacturing Practice (GMP)-compliant. Pharmaceutical design also 
includes perfect cleanability, process reproducibility proven by stringent documentation and 
the use of Food and Drug Administration (FDA)-approved materials. Another challenge is the 
miniaturization of pharmaceutical extrusion equipment, in particular for the development of 
formulations with new chemical entities [8]. While there is no need for a special co-extrusion 
design of the upstream equipment (feeders and extruders), the specific requirements for die 
and downstream equipment with regard to co-extrusion will be discussed. All equipment of 
a co-extrusion line needs to fit together and the extruders have to be positioned in a way 
that they can easily be connected at the die (Fig. 1). Therefore the overall design of the co-
extrusion line, fit for the dimensions of the production facility, is important. 
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Figure 1. Example of a co-extrusion line. 
 
Feeders  
 
In co-extrusion the material mix of each layer is fed separately into the barrel of an extruder. 
Materials for each specific layer can be either premixed in a fixed ratio or individually 
metered into the extruder. Feeding in a constant and accurate way is a challenging but very 
important aspect in pharmaceutical extrusion processes. Feeding is either starve-fed, where 
the rate is set by the feeders, or flood-fed where the extruder screw speed determines the 
output.  
Powders are mainly fed into the extruder using screw feeders which can be optimized by 
choosing the type of screws according to the powder characteristics. For powders with poor 
flow properties co-rotating twin screw feeders can be used instead of single screw feeders. 
An improved hopper design and discharging aids can also be built into the feeders to avoid 
bridging or other feeding problems. Feeders are controlled in a gravimetric or volumetric 
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way. The controller of a volumetric feeder imposes a constant rotation speed, which can 
result in high mass-flow fluctuations, whereas a gravimetric or loss-in-weight feeder 
monitors the weight fluctuation per time interval and modifies the rotation speed to keep 
the mass-flow rate constant. It is obvious that loss-in-weight feeders are typically preferred 
in pharmaceutical GMP installations. 
 
Extruders  
 
Extrusion processes can be categorized as either ram or screw extrusion. In ram extrusion 
high pressures are applied to displace a ram in order to push the heated material through a 
die. Screw extrusion uses one (single screw) or two (twin screw) screws to transport the 
material. Screw extruders are preferred over ram extruders since they provide more shear 
and intense mixing, resulting in a better homogeneity and temperature uniformity. The 
single screw extruder is the most widely used extrusion system in the plastics industry, while 
twin screw extruders (TSE) are preferred for pharmaceutical applications because of their 
high kneading and dispersing capacities, short residence time and -in case of intermeshing 
machines- their self-wiping sanitary screw profile [5]. TSE’s are starve-fed, which means the 
feed system determines the output rate. The screws of a twin screw extruder can be either 
co-rotating or counter-rotating [1]. In pharmaceutical industry the intermeshing co-rotation 
mode is preferred, since it provides intensive mixing and ensures almost complete emptying 
of the extruder, minimizing loss of highly valuable product. These extruders operate by a 
first in - first out principle and minimize the non-motion, thus preventing localized 
overheating of materials within the extruder. These advantages indicate that this type of 
extruders is the best option for pharmaceutical co-extrusion. 
INTRODUCTION –  HOT-MELT CO-EXTRUSION: PROCESS AND APPLICATIONS 
14 
 
The three basic functional screw element types are classified as forwarding, mixing and 
zoning. Forwarding elements are usually flighted, and they convey material from the feed 
opening towards the die. Mixing elements can be dispersive or distributive. In distributive 
mixing individual domains are unchanged, in dispersive mixing morphological units are 
broken down by shear and elongation. Mixing elements may have a balance of both 
properties. Furthermore mixing elements can be forwarding, neutral or reversing, the latter 
changing the direction of material flow by pushing the material backward. Zoning elements 
can be used to separate unit operations [9].  
Based on the design and function of the screws an extruder is typically divided into three 
sections along its length. In the feeding section the material will be transferred from the 
hopper to the barrel. Once the material enters the compression section it will begin to 
soften or melt. The temperature of this section is normally set at 30 - 60 °C above the glass 
transition temperature of amorphous polymers or the melting point of a semi-crystalline 
polymer [10]. This can be used as a rule of thumb although exceptions have been described 
[11, 12]. Of course intermolecular interactions also determine plasticizing or anti-plasticizing 
effects. In this section the mixing elements will perform their dispersive and/or distributive 
mixing operation. The molten material finally enters the metering section, where the 
pulsating flow is reduced to ensure a uniform delivery rate through the die cavity. The 
output rate of the extrudate is highly dependent on the channel depth and the length of this 
metering section. Especially in co-extrusion it is important to make sure that the design of 
the screws is ensuring a stable throughput. Sometimes a melt pump is used to reduce the 
pressure and throughput instability, called melt pulsation [13]. Apart from this technological 
solution, melt pulsation can also be prevented by constructional screw and barrel 
adaptations such as changing the length, diameter and pitch of the screws [14]. Mounting 
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intensive mixing elements results in a significant improvement of the homogenization of the 
processed material. In combination with special densification elements at the end of the 
screw melt pulsation can effectively be eliminated. 
 
Dies 
 
Before exiting the extruder the melt is pumped through a die, which is mounted at the end 
of the barrel, and is hereby exposed to high pressure. The geometrical design of the die will 
dictate the shape of the final product [10]. In co-extrusion the die design is crucial for 
shaping co-extrudates with the desired characteristics. A lot of different designs are possible, 
but for every design the rheological behavior and temperature distribution of both melts 
need to be modeled accurately. Another important aspect of co-extrusion is the contact 
surface between the materials, dictated by the shape of the co-extrudate, and the contact 
time of the materials in the die, which is illustrated by the difference between single- and 
multi-manifold dies.  
 
Figure 2. Schematic representation of a multi-manifold die and a single-manifold die. 
 
Two basic die types used in co-extrusion systems are multi-manifold dies and single-manifold 
dies (Fig. 2). Multi-manifold dies exhibit individual manifolds for each layer and each 
manifold is designed to distribute its polymer layer uniformly before combining with other 
layers. In most cases the layers are combined inside rather than outside the die in order to 
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prolong the thermal contact period and thus improve the interfacial adhesion between the 
layers. Since in a multi-manifold die the different layers are quite established prior to 
combination, migration is minimized and thus a very uniform distribution of layers is 
achievable, which is a major advantage for co-extrusion in pharmaceutical applications.  
In a single-manifold die only one manifold is present. In plastics it is often combined with a 
feedblock. In a feedblock with single-manifold die design a multilayer composite is formed in 
a combining adaptor prior to delivery to a flat die. The feedblock arranges the incoming melt 
streams in the proper sequence and balances the velocities of the components. The 
multilayer composite is then compressed into a rectangle and delivered to a flat die where 
the composite is spread and thinned to its final form. Currently there is a trend to more co-
extruded layers with micro-layer structures containing up to ten layers of a thickness down 
to 1 micron produced by multilayer co-extrusion dies [15]. One of the most important 
considerations in feedblock co-extrusion is layer uniformity. Layer non-uniformity can be 
corrected by feedblock profiling in order to shape the polymer composite prior to entering 
the die [16].  
The classification of dies is not only made by the distinction between single- and multi-
manifold, they can also be classified by their shape. Flat dies (Fig. 3) convert materials from 
the circular shape at the end of the barrel into a thin wide sheet and are thus suitable to 
produce films and lamination systems. These are used for packaging materials and for 
transdermal and dissolvable film applications. 
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Figure 3. Example of a flat die. 
 
Since the material path along the centerline is shorter in comparison with the one at the 
edges these dies need a design that prevents the sheet from being thicker in the center than 
at the edges in order to achieve a uniform distribution of material across the width [17]. 
When the polymer melt is extruded through a slit die onto highly polished cooled rolls which 
form and wind the finished sheet, the process is known as cast film extrusion. When the 
melt is extruded vertically into a tubular film and inflated by air, the process is known as 
blow film extrusion [5].  
For medical device applications (e.g. tubings) annular dies are used. Side fed dies and spiral 
mandrel dies (Fig. 4) are used in applications where a substrate needs to be coated or in co-
extrusion. 
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Figure 4. Thermo Fisher Scientific® co-extrusion spiral mandrel die with cylindrical core and annular coat. 
(Reprinted with permission of Thermo Fisher Scientific®) 
 
The mixing effect of the spiral distribution system provides improved product uniformity, 
which is very advantageous for pharmaceutical applications. For the design of a die the 
thickness uniformity, residence time and residence time distribution are important criteria. 
In a spiral mandrel type die the material is exposed to a larger residence time distribution, 
which can cause degradation because of the longer exposure to the processing temperature 
in the die [18].  
Two exit phenomena that can occur when the processed material leaves the co-extrusion 
die, need to be considered: extrudate swell and sharkskin. These phenomena are common in 
polymer processing, but need extra attention in co-extrusion as they can occur in each of the 
co-extruded layers.  
Extrudate swell, also known as die swell, is a situation where the diameter of the extrudate 
increases upon exiting the die. The polymer melt is compressed when entering the die, 
followed by a partial recovery (i.e. swell) to the former shape and volume after exiting the 
die. It is an entropy-driven phenomenon that occurs when the individual polymer chains, 
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due to their viscoelastic properties, recover via relaxation from the deformation caused by 
the rotating screw inside the barrel. The extent of extrudate swell depends on external 
factors as well as on factors intrinsic to the polymer [19].  
The other exit phenomenon, sharkskin, is an extrudate surface defect characterized by small 
scale and high frequency roughness. As an explanation for its occurrence it was claimed that 
sharkskin results from the cracking of the fluid at the die exit, under action of the high 
tensile stresses which may develop in this zone [20]. 
 
Downstream processing equipment  
 
Currently several downstream solutions for shaping extrudates into oral dosage forms are 
used in pharmaceutical industry. When extrudates are milled and subsequently tabletted or 
filled into capsules, the process is discontinuous. In pharmaceutical applications, and more 
specific in co-extrusion, one of the major challenges is shaping the final product in a 
continuous way. The following techniques have already been applied in hot-melt extrusion 
and could be extended to co-extrusion. 
 
Cooling and conveying 
Chill rolls are used as an intermediate process step, to cool down and control the 
temperature of extruded films. Two rolls with a defined slit opening, temperature and speed 
create a temperature gradient throughout the extrudate to cool it in a controlled way. Highly 
polished rolls that apply a very well controlled cooling are advantageous to maintain product 
characteristics and can immediately process thin extruded sheets. If the extruded material is 
brittle the sheets will form flakes on an agitated conveyor belt. These flakes need to be 
milled or crushed, and afterwards the powder can be used for tableting or capsule filling. 
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Controlling the cooling rate is of major importance when the amorphous nature or 
crystallinity of the API has an impact on the in-vivo performance of the drug. Film thickness 
can be adjusted by changing the rotating speed of the chill rolls. A rod shaped co-extrudate 
can be conveyed using a conveyer belt and cooled in a water bath or by a cooling ring or air 
tunnel, before further processing. 
 
Pelletizing 
Using a pelletizing/cutting system co-extruded strands can be turned into small pellets 
(down to 0.5 mm) in a continuous way. These pellets can be milled, filled into capsules as 
such or further modified by spheronization [21].  
A traditional pelletizer consists of blades on a helical rotor. A drawback of this system is that 
uniform pellets with constant dimensions can only be obtained for rigid materials, as 
extrudates composed of soft material will yield deformed pellets. In continuous mode a high 
throughput rate can be obtained, but the edges of the pellet are not straight. When cutting 
in a start/stop mode a lower throughput rate and straight edges can be obtained. Challenges 
are abrasion of the cutting blades and clogging of material. Teflon-coated knifes can be used 
to avoid clogging effects, while an air pressure nozzle can avoid accumulation of the pellets 
in the cutting zone. These improvements will tackle the current challenges and offer a widely 
applicable pelletizing system.  
Although spheronization of pellets at elevated temperatures in a traditional spheronizer has 
proven to be a successful processing step [22, 23], currently die face cutters are available 
post-extrusion for the production of spheronized micro-pellets. The strand is cut 
immediately after it leaves the nozzle. Spheronization occurs as a result of die swelling. 
Recently a novel die has been designed to include a direct pelletization/spheronization step. 
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Cutting of the hot, still molten strand has been achieved with a rapidly rotating cutter knife. 
The granules instantly form perfectly shaped micro pellets due to the action of surface 
tension and the shrinkage due to solidification. The importance of a proper temperature 
control of the extrusion die has been shown by Radl et al. [24]. 
In case of annular shaped co-extrudates a traditional type of pelletizer is less suitable, since 
the inner layer of the extrudate may be pushed out of the outer layer. Cutting of co-
extrudates requires a punching system or a pelletizing system with a very sharp knife in 
order not to put too much pressure on the inner layer and to obtain pellets with constant 
composition and dimensions. Therefore this technique is not ideal for co-extrudates 
composed out of hard or brittle materials. Co-extrudates cut into small mini-tablets have 
open sides, which has an influence on the release pattern of the inner layer [11]. 
 
Calendering 
Calendering is the downstream solution where the molten co-extruded strand is forced 
between temperature-controlled rolls to produce sheets that already contain single tablet 
cores. Calendering is a further step towards a continuous process by allowing immediate 
final shaping of the extrudate by calendar rolls that contain tablet- or pill-shaped cavities. 
This technique is already used in the plastics or confectionary industry in order to produce 
monolithic shapes. In pharmaceutical applications the Meltrex® technology offers 
calendering as one of the possible solutions to shape the molten strand, immediately after 
leaving the extruder [25]. There is always some waste material at the sides of the tablets or 
pills, which is a disadvantage when working with highly valuable active ingredients, but the 
continuous on-line shaping of the product via calendering is a major advantage over 
pelletizing, where a subsequent process step is inevitable to obtain a final dosage form.  
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In case of co-extrusion calendering can be a good solution since the shaping by the rolls will 
make sure that the outer layer is entirely surrounding the inner core (Fig. 5). Yet, it has to be 
mentioned that for drug delivery systems where the coat steers the drug release rate from 
the core, it is challenging to obtain a coat that completely occludes the core by means of 
calendering since it is difficult to produce a completely sealed outer layer via this technique. 
Nevertheless calendering has an advantage over pelletizing of the co-extrudates  where both 
sides are open and the inner layer of the co-extrudate is exposed. 
 
 
 
Figure 5. Example of calendering in co-extrusion. 
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Injection and blow molding  
During injection molding the molten plastic is injected into a cavity mold at high pressure. 
The material cools and solidifies in the cavity. The final product is removed from the cavity 
after the mold has been opened. This technique is the most reliable option to obtain final 
dosage forms with a unique shape, perfectly matching the specified dimensions. It was 
transferred from the plastics industry and can be used in the pharmaceutical industry for the 
production of conventional and controlled-release dosage forms. It can be used as an 
economically advantageous manufacturing technique or as an approach to new drug 
delivery systems [26]. Quinten et al. demonstrated that injection molding of thermoplastic 
pharmaceutical formulations based on ethylcellulose (EC) and polyethylene oxide (PEO) is a 
promising technique to prepare sustained release matrix tablets [27]. Vaz et al. have shown 
that co-injection molding is a successful way of producing a double layer core/coat drug 
delivery device which offers a lot of opportunities for processing of co-extrudates [28]. 
Compared to calendering the higher equipment cost for the two-step co-injection molding 
process is the major drawback. Co-injection molding is commercially used for the 
manufacturing of the Egalet® technology (cfr. page 28).  
Co-extruded tubing can be shaped by means of blow molding, mainly used for the 
production of containers. The tubing is extruded into an open mold. After the mold has been 
closed, compressed air is blown into the open end of the tube, thus expanding the viscous 
material to the walls of the cavity, forming it into the desired shape of the container. When a 
product has specific shape or dimension requirements, molding is the best alternative as a 
downstream processing technique. 
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Process monitoring and control 
 
Variables that need to be controlled throughout the entire process are feed rates of the 
ingredients, barrel and die temperatures, motor speed and specific parameters for the 
downstream equipment, e.g. extrudate diameter control by a laser gauge. Parameters that 
need to be monitored are actual feed rate and temperatures, screw speed, torque and die 
pressure.  
Since the FDA introduced its PAT initiative, several process analytical technology tools for 
pharmaceutical hot-melt extrusion processes were evaluated. Several research groups have 
proven that Raman spectroscopy is a valuable tool for in-line monitoring of API 
concentration and solid state during a pharmaceutical hot-melt extrusion process [29, 30]. 
Using on-line spectroscopic techniques, PAT can also lead to a better understanding of the 
HME process. Currently a lot of research on PAT in hot-melt extrusion is being performed. 
Terahertz pulsed imaging [31] seems a promising technique for analyzing the final co-
extruded product in the future, since it not only characterizes the outer but also the inner 
layer of the co-extrudate. 
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MATERIALS USED IN CO-EXTRUSION 
 
To be processed by HME, a material must deform in the extruder and solidify upon exiting 
the die. HME formulations for pharmaceutical dosage forms are mixtures of an API and 
functional excipients, mainly classified as matrix carriers, plasticizers and other additives 
(e.g. anti-oxidants and release modifying agents).  
An appropriate carrier selection is important in the development of a hot-melt extruded 
dosage form. Carrier materials used can be polymeric materials - generally thermoplastic 
polymers exhibiting a low glass transition temperature (Tg) or melting point - or 
thermodeformable waxes. The properties of the carrier determine the processing conditions 
and drug release kinetics from the final drug product [1]. Besides the glass transition 
temperature, the melt viscosity determines the processing temperature of a polymer, since 
the torque produced within the extruder - which depends on the viscosity of the melt - 
determines whether extrusion is possible or not [4].  The main challenge for a co-extrusion 
process is to find appropriate polymer combinations, taking into account the pharmaceutical 
aspects (e.g. meeting the required drug release characteristics), regulatory requirements 
(e.g. fulfilling the Generally Recognized As Safe (GRAS) status) as well as some technical 
considerations (e.g. similar extrusion temperature at the die, melt viscosity matching, 
adhesion between layers). 
The use of polymeric carriers may require the incorporation of a plasticizer - a low molecular 
weight compound able to decrease Tg and melt viscosity of a polymer by increasing the free 
volume between polymer chains - to improve extrusion conditions (lower temperature and 
less torque) or to improve the physical and mechanical properties of the final drug product. 
Citrate esters, fatty acid esters and sebacate esters, but also low molecular weight 
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polyethylene glycols and surfactants are commonly used as plasticizers in pharmaceutical 
dosage forms [1]. 
Additives can be added to the formulation for different reasons, e.g. the stability of polymers 
that are prone to degradation can be improved with the addition of anti-oxidants [32]. Other 
functional excipients can modify the drug release rate, e.g. viscosity increasing agents can be 
incorporated into a polymer matrix to reduce an initial burst release.  
For each individual component, including the API, thermal stability is a prerequisite to be 
processed via HME. However, the short processing times using twin screw extruders may not 
limit all thermolabile compounds [1]. 
For the development of a co-extruded formulation some additional technical considerations 
have to be taken into account: (a) each melt needs to flow through the co-extrusion die 
under the same temperature conditions, (b) the melt viscosity of the different layers need to 
match to avoid layer non-uniformity [16], (c) an adequate adhesion between the layers is 
indispensable to avoid separation during downstream processing [33], (d) the degree of 
interdiffusion and migration between the co-extruded layers needs to be considered and (e) 
shrinkage of both layers should not differ too much [34]. Taking into account these extra 
considerations it is obvious that formulating the different layers in co-extrusion is not always 
straightforward. 
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MEDICAL AND PHARMACEUTICAL APPLICATIONS 
 
In medical applications extrusion was already used for years to produce balloon tubing and 
single- or multi-lumen tubing, to be used for minimally invasive diagnostic and therapeutic 
procedures. Now the technology has advanced to co-extrusion in order to create tubing with 
multiple layers of different materials or with colored stripes of the same material. Co-
extruded tubing is especially useful for angioplasty, placing stents, guiding catheters and 
dialysis [35]. For multiple layer tubings the different materials (e.g. silicone, nylon, 
polyurethanes) are selected to be compatible to prevent delamination of the tubing. 
Chemically dissimilar materials can be extruded together using a tie layer as an intermediate 
layer between the core layer and the outer layer. The co-extruded multilayer tubings show 
enhanced performance characteristics, since materials with different but complementing 
properties can be combined. A tri-layer tubing with a thin hydrophilic surface coating can 
e.g. provide low friction for the advancement of a guide wire or catheter through the lumen 
without comprising strength and stiffness. The stripes on a co-extruded tubing can be 
coloured, contain radiopaque materials that make the tubing visible on X-rays or ensure 
built-in lubricity. Co-extrusion is gaining importance in tubing for medical use with multiple 
layers and thinner walls. Therefore unprecedented levels of dimensional accuracy and flaw 
detection are required. As tubes get smaller, and walls and layers get thinner, medical tubing 
manufacturers have to put more emphasis on gauging for quality control [36]. 
In medical devices there is a trend to combination products where a medical device is loaded 
with a drug in order to deliver it at the site of action or to influence the release of the loaded 
drug. Some examples are drug-eluting coronary stents, contraceptive implants, vaginal rings 
and transdermal patches. The design of advanced drug-delivery systems has moved to the 
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forefront in pharmaceutical technology. In the design of such systems, co-extrusion and 
supporting downstream solutions can provide unique advantages.  
The commercially available drug products that are produced by means of co-extrusion are in 
most cases combinations of a drug with a medical device, e.g. Implanon® and Nuvaring®. 
Implanon® (Schering-Plough), a non-biodegradable flexible rod that contains etonogestrel, 
provides contraceptive efficacy during a period of 3 years [37].  The rod is 4 cm in length by 2 
mm in diameter and consists of a solid core of ethylene vinyl acetate (EVA) with embedded 
etonogestrel crystals. The core is surrounded by an outer ethylene vinyl acetate membrane 
that controls the release rate. The ends of the rod are not covered by an outer layer to allow 
an initial rapid hormone burst after the implant is inserted in the arm, just under the skin 
[38]. Nuvaring® (MSD), a contraceptive intravaginal ring releasing etonogestrel and ethinyl 
estradiol for 21 days, consists of a coaxial fiber, prepared by ethylene vinyl acetate 
copolymers. The coaxial fiber consists of a core polymer - with two steroids incorporated in a 
molecularly dissolved state - that is enveloped with a thin polymer membrane. The outer 
EVA membrane regulates drug release and provides a near zero-order rate of release over a 
21-day period. This polymeric reservoir system is prepared by co-extrusion, consisting of two 
single screw extruders connected to a spinning block. The molten polymers for core and 
membrane are delivered to two gear pumps and subsequently combined in a spinneret, 
thereby forming the coaxial fiber [39]. Following extrusion, the rod is cut and end-fused to 
create a ring [40]. 
Some pharmaceutical products are composed of two extruded layers, but these were not 
extruded simultaneously. The Egalet® technology, an erosion-based delayed-release system, 
consists of an impermeable shell with a plug of active drug as the core of the drug delivery 
system [41]. The shell consists of polyethylene glycol monostearate combined with higher 
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molecular weight polyethylene glycols and polyethylene oxides. During the injection molding 
production process the shell is formed during the first injection in the mold and afterwards 
the core is molded during a second injection. This manufacturing process provides a high 
accuracy in the dimensions of the matrix, which is very important since the drug delivery 
system is designed to show a continuous zero-order release, directly proportional to the 
area eroded [42]. Jadelle, a non-biodegradable, flexible, subdermal levonorgestrel implant 
for contraception consists of two rods of dimethylsiloxane/methylvinylsiloxane copolymer. 
The core of each rod is a 1:1 physical mixture of silicone rubber elastomer and 
levonorgestrel, and is covered with a thin silicone rubber tubing. The rod is cured in an oven 
to cross-link tube and drug core. After the open ends of the tubing are sealed with medical 
adhesive the implants are sterilized [43]. 
Only recently co-extrusion is gaining importance in the production of oral drug products. So 
far, there are no co-extruded dosage forms for oral use on the market, but several research 
studies have been performed in this field. Quintavalle et al. characterized hot-melt co-
extruded cylindrical systems for controlled drug delivery. The sustained release profile was 
obtained by extruding two concentric theophylline-loaded matrix formulations: an inner 
hydrophilic polyethylene glycol-based matrix combined with an outer lipophilic layer, mainly 
consisting of microcrystalline wax. A screening of devices differing in dimensions and relative 
proportions of inner and outer layer was performed based on in vitro drug release. The 
release mechanisms were studied using a mathematical model [7, 44]. Iosio et al. produced 
pellets with two cohesive layers via co-extrusion/spheronization. An inert layer of 
microcrystalline cellulose, lactose and water was combined with a second layer containing a 
self-emulsifying system of the model drug vinpocetine. In order to evaluate the effects of 
formulation variables an experimental design was used. In vitro dissolution and in vivo tests 
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demonstrated that it was possible to produce bilayered cohesive self-emulsifying pellets by 
means of co-extrusion/spheronization, with improved solubility and in vivo bioavailability of 
the poorly water-soluble model drug [22]. A recent study by Dierickx et al. described the 
successful preparation of fixed-dose combination mini-matrices via co-extrusion [11]. A 
core/coat dosage form was developed, wherein the core and coat exhibited sustained and 
immediate release properties respectively, using a combination of polycaprolactone (core) 
and polyethylene oxide/polyethylene glycol (coat). The same research group also developed 
by means of co-extrusion a multilayered dosage form characterized by a dual release profile 
of the same drug. The co-extrudates consisted of two concentric polymer matrices: a core 
having a lipophilic character, and a coat with a hydrophilic character. The maximum drug 
load in core and coat was determined by the extrusion temperature and the die dimensions, 
while adhesion between core and coat was mainly determined by the drug load and the 
extrusion temperature [45].  
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FIXED-DOSE COMBINATION PRODUCTS FOR COMBINATION THERAPY 
 
The production of oral drug delivery systems via co-extrusion offers the opportunity to 
produce fixed-dose combination products. Combination therapy with two or more agents 
having complementary mechanisms of action can extend the range of therapeutic options in 
the treatment of numerous human diseases. Combination therapy is increasingly recognized 
as a major advantage, not only for life cycle management of drugs but also for therapeutic 
reasons. One major benefit of combination therapies is that they reduce development of 
drug resistance, since a pathogen or tumor is less likely to have resistance to multiple drugs 
simultaneously [46]. The combination of pharmaceutical products offers enhanced efficacy 
and improved selectivity - and therefore reduced toxicity and side effects - of the drugs [47, 
48].  
Fixed-dose combination (FDC) products contain two or more active pharmaceutical 
ingredients in a single dosage form. Oral combination drug delivery systems have proven to 
be highly beneficial in the treatment of life threatening diseases such as cancer, AIDS and 
tuberculosis. Additionally combination drug therapy has been successfully introduced for 
diseases such as diabetes, heart diseases, central nervous system disorders and to treat 
microbial infections [47]. They become increasingly important, given that 26 out of the 101 
FDA-approved New Drug Applications (NDAs) in 2010 were FDC products [49]. The 
combination of two or more drugs with complementary modes of action optimizes 
treatment and offers convenience, reduced dosing unit burden and cost savings to the 
patient. For tuberculosis treatment the (WHO) recommends the use of a 4-drug FDC 
preventing patients to be selective in their choice of drugs and the resulting acquisition of 
drug resistance due to monotherapy [50]. Also for oral anti-diabetic therapy fixed-dose 
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combination dosage forms have shown to simplify pill regimen and improve patient 
adherence [51, 52]. These advantages are especially important for the aging population in 
developed countries needing multiple medications to treat age-related diseases and co-
morbidities. In this respect the use of polypills - containing a statin, blood pressure-lowering 
agents and aspirin - and their impact on adherence was also positively evaluated [53]. 
Sometimes two drugs are also combined to minimize the potential for abuse of the principal 
active component, e.g. the addition of naloxone, an opioid antagonist, to buprenorphine to 
prevent the possibility of injecting the product by opioid addicts.  
An important disadvantage of FDC products is the reduced dosing flexibility, which is often 
compensated by the development of multiple strength combinations. However, for 
treatments requiring frequent dose adjustments FDC products are not very useful. Another 
disadvantage might be that, since the FDC contains multiple drugs in one tablet, the tablet 
size may be too large to swallow for pediatric and elderly patients. Additionally it is also 
more difficult to determine which drug caused an adverse drug reaction [49]. Moreover, the 
goal of a combination therapy is additive benefit or preferentially synergy, but the 
substantial risks need to be recognized. Treatments that are safe when used alone can 
promote drug-drug interactions, which may induce changes in pharmacokinetics [54].  
As a regulatory strategy for FDC products, establishing bioequivalence of drugs in an FDC 
product to drugs co-administered as individual entities is a very common approach. In 
addition possible food effects need to be considered as well [49]. Investigational drugs are 
traditionally tested for efficacy in add-on trials, in which the new drug added to a standard 
treatment is compared with the standard regimen alone. But, for diseases in which 
innovative targeted combination therapies are developed such clinical studies will often be 
unethical because of the potential to promote the development of resistance. Therefore FDA 
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has drafted a guidance for industry concerning the co-development of two or more 
unmarketed investigational drugs for use in combination, providing some flexibility in 
establishing the contribution of the individual drugs [55]. The additional uncertainty 
introduced by this co-development approach should not be underestimated, because it will 
not be possible to fully characterize the effects of the individual components of the 
combination. For this reason co-development should be used only for treatments of serious 
life-threatening diseases. FDA recommends adequate pharmacovigilance plans to address 
the risks linked to co-development [55].  
Formulation and manufacturing of an FDC is a challenge and is critical to ensure unaffected 
bioavailability of each of the components. Incorporation of several drugs in one film-coated 
tablet might compromise bioavailability of one component, e.g. when a water-insoluble 
component is incorporated with highly water-soluble drugs [56]. Therefore several 
innovative drug delivery systems have been developed. Numerous bilayer tablets have 
shown their potential to incorporate two drugs in different layers and provide adequate drug 
release for each component, by e.g. compressing granules containing different drugs and 
excipients [57]. Multilayered tablets with a drug-loaded film coat surrounding a core 
containing the second drug in an appropriate matrix have been successfully developed and 
marketed [58]. Another multidrug and multikinetics delivery system developed is the Dome 
Matrix®, where tablets having a specific shape are assembled into a multimodule system 
[59]. Filling controlled- and immediate-release prills, loaded with different drugs, into a 
capsule also proved to be a successful method to develop a fixed-dose combination [60]. The 
commercially available PRODAS® technology is a multi-unit system combining the benefits of 
tableting technology within a capsule as a number of mini-tablets are combined in a hard 
gelatin capsule. Several innovative technologies even use capsule-in-capsule systems to offer 
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multiphase multicompartment combination product delivery systems (InnerCap™ and 
DuoCap™). However, as all of these delivery systems require a multistep production process, 
co-extrusion can be an attractive alternative. 
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DISCUSSION 
 
Drug development was never more challenging as pharmaceutical production processes with 
a better efficiency must be developed, while drug substances are often more difficult to 
process because their often poor bioavailability. Hot-melt co-extrusion is the perfect answer 
to these challenges, as it provides the possibility to formulate a drug substance as a solid 
dispersion via a continuous process. Since combination products are gaining importance 
therapeutically and optimal drug delivery is a prerequisite for a new drug product, co-
extrusion is a very promising formulation technique. When combining several drug 
substances in different matrices the release patterns of the drug delivery systems can be 
tailored to achieve the maximum therapeutic efficiency via a patient-friendly dosage form. 
Although optimization of downstream processing after co-extrusion remains a point of 
attention, there are several interesting options to obtain monolithic systems or 
multiparticulates, the latter having the advantage of dosing flexibility and small size, 
important for specific populations. 
Barriers to the implementation of co-extrusion in the pharmaceutical industry are the 
process knowledge needed, the significant investment initially required and the limited 
number of established-use thermoplastic polymers available. 
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ABSTRACT 
 
Chapter 1 evaluates hot-melt co-extrusion as a technique for the production of fixed-dose 
combination products, using ethylcellulose as a core matrix former to control the release of 
metoprolol tartrate and a polyethylene oxide-based coat formulation to obtain immediate 
release of hydrochlorothiazide. By lowering the concentration of the hydrophilic additive 
polyethylene oxide in the plasticized ethylcellulose matrix or by lowering the drug load, the 
in vitro metoprolol tartrate release from the core was substantially sustained. The in vitro 
release of hydrochlorothiazide from the polyethylene oxide/polyethylene glycol coat was 
completed within 45 min for all formulations. Tensile testing of the core/coat mini-matrices 
revealed an adequate adhesion between the two layers. Raman mapping showed no 
migration of active substances. Physicochemical state characterization indicated that the 
crystalline state of metoprolol tartrate was not affected by thermal processing via hot-melt 
extrusion, while hydrochlorothiazide was dissolved in the coat. These physicochemical 
characteristics were confirmed during the stability study. Considering the bioavailability of 
metoprolol tartrate after oral administration to dogs, the different co-extruded formulations 
offered a range of sustained release characteristics. Moreover, high metoprolol tartrate 
plasma concentrations were reached in dogs allowing the administered dose to be halved. 
Interestingly, the resulting metoprolol tartrate plasma concentrations could be predicted 
based on the observed in vitro release kinetics, using an appropriate mathematical model. 
The latter takes into account drug transport within the dosage form as well as the in vivo 
fate of the drug.  
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INTRODUCTION 
 
The need for novel combination therapies, primarily focusing on fixed-dose combinations 
(FDC), has been reported by various authors and is seen as a driver for innovative drug 
development [1, 2]. Besides their benefits in life cycle management, FDC products have 
shown to improve patient adherence by decreasing the number of required pills and thus 
reducing the complexity of the medication regimen [3]. Fixed-dose combinations offer 
benefits to a lot of drugs due to the additive nature of therapeutic effect and the reduced 
level of side-effects associated with the use of complementary drugs [4]. The application of 
oral sustained release formulations has improved patient compliance due to a lower dosing 
frequency and a reduced incidence of adverse side effects. Sustained release formulations 
have shown to offer many other advantages over conventional drug products, such as the 
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controlled administration of a therapeutic dose at a desired delivery rate in order to gain 
more constant plasma concentrations of the drug. Moreover, the production of sustained 
release multiparticulate dosage forms is advantageous since in vivo the subunits spread into 
the gastrointestinal tract as soon as the dosage unit, e.g. capsule or tablet, disintegrates. 
Since high local drug concentrations are avoided, less inter- and intra-subject variability and 
a decreased risk of dose dumping can be expected [5]. 
While hot-melt extrusion (HME) has proven to be a successful processing technique used in 
pharmaceutical industry to produce drug products in a continuous way, co-extrusion is quite 
new in pharmaceutical applications [6, 7]. Nevertheless co-extrusion of polymers is widely 
applied in the plastics and packaging industry. The pharmaceutical co-extrusion process 
consists of the simultaneous hot-melt extrusion of two or more drug-loaded formulations 
creating a multilayered extrudate. HME as a continuous manufacturing technology has 
shown some other major advantages over conventional techniques, like improving the 
bioavailability of poorly water-soluble drugs via molecular dispersions [8], without the 
requirement for processes based on organic solvent or aqueous spray drying.  Moreover via 
HME matrix formulations can be manufactured using polymers that act as drug depots [9]. 
The added value of co-extrusion is that it allows to modulate the release of each drug 
independently, to enable simultaneous administration of non-compatible drugs and to 
produce fixed-dose combinations in a continuous single-step process. By processing the co-
extrudate into mini-matrices that can be easily filled into gelatin capsules a multiparticulate 
formulation is created. A specific challenge during co-extrusion is to establish a core/coat 
polymer combination fit for purpose considering required release characteristics of the 
incorporated drugs, similarity in extrusion temperature and appropriate adhesion between 
the layers. So far, no co-extruded dosage forms for oral use are on the market. In this study a 
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contribution is made to enable the use of co-extrusion in pharmaceutical industry for the 
production of oral FDC drug products that offer multiple release profiles.   
The aim of this study was to evaluate the use of co-extrusion for the manufacturing of a 
fixed-dose combination drug product for oral application, using a core matrix former that 
offers a range of controlled release profiles for highly water-soluble drugs. For this purpose 
ethylcellulose, a thermoplastic polymer that has been intensively used as a matrix former in 
hot-melt extrusion [10, 11], was combined with polyethylene oxide as a hydrophilic additive 
and metoprolol tartrate as model drug. The combination of this beta-blocker with the 
diuretic hydrochlorothiazide is well known [12]. It offers the opportunity for a co-extrudate 
with hydrochlorothiazide incorporated in the coat as immediate release model drug and 
metoprolol tartrate incorporated in the core as model for a highly water-soluble drug. The in 
vitro performance of the different formulations was assessed. The physicochemical state of 
the model drugs in the formulations was characterized using modulated differential scanning 
calorimetry (MDSC), X-ray diffraction (XRD) and Raman spectroscopy. Furthermore, the 
physical stability of the co-extruded mini-matrices was monitored during 6 months storage 
at 25 °C/60 %RH and 40 °C/75 %RH. Finally, the bioavailability of the different formulations 
was evaluated after oral administration to dogs and compared to a commercially available 
fixed-dose combination product. In addition, a mathematical model considering the 
controlled release of metoprolol tartrate from the dosage form and its fate in vivo was 
developed and used to predict the resulting drug plasma profiles, based on the in vitro 
results and in vivo parameters reported in literature. 
 
 
CHAPTER 1 – HOT-MELT CO-EXTRUSION FOR THE PRODUCTION OF FIXED-DOSE COMBINATION PRODUCTS 
WITH A CONTROLLED RELEASE ETHYLCELLULOSE MATRIX CORE 
48 
 
MATERIALS AND METHODS 
 
Materials  
 
Metoprolol tartrate (Esteve Quimica, Barcelona, Spain) and hydrochlorothiazide (Utag, 
Amsterdam, the Netherlands) were selected as sustained release and immediate release 
model drugs, respectively. Ethylcellulose (Ethocel® std 10, Colorcon, Dartford Kent, United 
Kingdom), dibutyl sebacate (Sigma-Aldrich, Bornem, Belgium), polyethylene oxide 1M (MW: 
1000000 g/mol, SentryTM Polyox® WSR N12K, Colorcon, Dartford Kent, United Kingdom), 
polyethylene oxide 100K (MW: 100000 g/mol, SentryTM Polyox® WSR N10, Colorcon, 
Dartford Kent, United Kingdom), polyethylene glycol 4K (MW: 4000 g/mol, Fagron, 
Waregem, Belgium), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft 
copolymer (Soluplus®, BASF, Ludwigshafen, Germany), poloxamer 188 (Lutrol F68®, BASF, 
Ludwigshafen, Germany) and an 8:2 blend of polyvinyl acetate and polyvinylpyrrolidone 
(Kollidon SR®, BASF, Ludwigshafen, Germany) were used as excipients.  All other chemicals 
were of analytical grade.  
 
Hot-melt co-extrusion 
 
Co-extrusion was carried out with two co-rotating, fully intermeshing, Prism Eurolab 16mm 
twin screw extruders (ThermoFisher Scientific, Karlsruhe, Germany), both connected to a co-
extrusion die (Guill, West Warwick, USA). The co-extrusion die combined both layers into a 
rod-like co-extrudate consisting of a core and a concentric coat. The heating segments of 
both extruders were heated to 80/90/100/100/100/100 °C from feed opening to die-end. 
The co-extrusion die was heated to 100 °C. Both formulated premixes were fed separately 
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into the corresponding extruder by a Brabender Flexwall® loss-in-weight powder feeder 
(Duisburg, Germany) at a feed rate of 200 g/h for the coat and 300 g/h for the core material. 
A screw speed of 40 rpm for the extruder producing the outer layer and 150 rpm for the 
extruder producing the inner layer was used. The core of the co-extrudate, with a diameter 
of 3 mm, was surrounded by a coat with a thickness of 0.5 mm, which led to a total co-
extrudate diameter of 4 mm. Four different co-extrudates were manufactured consisting of 
a specific core and coat formulation, by combining the following components in different 
concentrations: ethylcellulose (EC), dibutyl sebacate (DBS), polyethylene oxide (PEO), 
polyethylene glycol (PEG), metoprolol tartrate (MPT) and hydrochlorothiazide (HCT) (Table 
1). After cooling down the co-extruded rod to room temperature, the cylindrical co-
extrudate was manually cut into mini-matrices of 2 mm length. Those mini-matrices had an 
average weight of 27.2 mg (SD = 1.8 mg, n = 20). 
 
 Matrix Drug load Drug dose 
Formulation A Core 53% EC 27% DBS 20% PEO1M 30% MPT 200 mg 
Coat 85% PEO100K  15% PEG 4K 5.6% HCT 25 mg 
Formulation B Core 62% EC 33% DBS 5% PEO 1M 30% MPT 200 mg 
Coat 85% PEO100K  15% PEG 4K 5.6% HCT 25 mg 
Formulation C Core 53% EC 27% DBS 20% PEO1M 15% MPT 200 mg 
Coat 85% PEO100K  15% PEG 4K 2.8% HCT 25 mg 
Formulation D Core 62% EC 33% DBS 5% PEO 1M 30% MPT 100 mg 
Coat 85% PEO100K  15% PEG 4K 11.2% HCT 25 mg 
Reference Zok-Zid® (Pfizer, Brussels, Belgium) MPT* 200 mg 
HCT 25 mg 
* Original reference product contained metoprolol succinate; dose calculated as metoprolol tartrate. 
Table 1. Composition of test and reference formulations and drug dose administered during the in vivo study. 
Formulation components are ethylcellulose (EC), dibutyl sebacate (DBS), polyethylene oxide (PEO), 
polyethylene glycol (PEG), metoprolol tartrate (MPT) and hydrochlorothiazide (HCT). 
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In vitro drug release 
 
In vitro dissolution was performed using United States Pharmacopeia (USP) dissolution 
apparatus 1 (baskets). The equipment consisted of an Evolution 6300 dissolution system 
(Distek, New Brunswick, New Jersey, USA) coupled with an Evolution 4300 automatic 
dissolution sampler (Distek, New Brunswick, New Jersey, USA). The temperature of the 
dissolution medium (900 ml) was maintained at 37 ± 0.5 °C while the rotational speed of the 
baskets was set at 100 rpm. For the first hour a 0.1 N solution of hydrochloric acid (pH 1) was 
used as dissolution medium in order to mimic the pH of the stomach. Afterwards the baskets 
containing the mini-matrices were transferred to vessels filled with phosphate buffer pH 6.8 
(USP) as a dissolution medium, to which they were exposed for the next 23 hours. Samples 
(filtered using Distek 45 µm filters) of 5 ml were withdrawn at 5, 10, 15, 20, 30, 45 and 60 
minutes for the determination of hydrochlorothiazide in the first dissolution medium and at 
1, 2, 4, 6, 8, 12, 16, 20 and 24 h for the determination of metoprolol tartrate in the second 
dissolution medium. The inner layer extrudate was analyzed separately to cover for the 
metoprolol tartrate release during the first hour. Samples were analyzed 
spectrophotometrically at 316.6 nm and 222 nm respectively, by an ultraviolet (UV) -
spectrophotometer, type UV-1800 (Shimadzu, Deurne, Belgium), using an appropriate 
calibration curve for quantification of hydrochlorothiazide and metoprolol tartrate, 
respectively. Each experiment was performed in triplicate. 
 
Modulated differential scanning calorimetry 
 
The crystallinity of the drug in the matrices and the thermal behavior of pure compounds, 
physical mixtures and corresponding extrudates were studied using a differential scanning 
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calorimeter Q2000 V24.8 equipped with a refrigerated cooling system (TA Instruments, 
Leatherhead, UK). Nitrogen was used as a purge gas through the DSC cell (50 ml/min) and 
the refrigerated cooling system (RCS) unit (300 ml/min). Samples (± 5 mg) were run in 
hermetically closed Tzero pans with perforated lid, supplied by TA Instruments, with an 
underlying heating rate of 2 °C/min. The modulation period and amplitude were set at 60 s 
and 0.318 °C, respectively (heat-iso method). Mass of sample pan and empty reference pan 
were taken into account. Temperature and enthalpy calibration was performed with an 
indium standard, whereas calibration of the heat capacity was performed using a sapphire 
standard. MDSC data were analyzed using the TA instruments Universal Analysis 2000 V4.7A 
software. Melting enthalpies were determined in the total heat flow signal. Melting 
temperatures were reported as peak temperatures. The glass transition temperature 
corresponds to the temperature at the midpoint of the heat capacity change (or Cp jump). 
 
X-ray diffraction 
 
Crystallinity was analyzed using X-ray diffraction (XRD) on pure compounds, physical 
mixtures and corresponding extrudates. X-ray diffraction was performed on a D5000 
diffractometer with Cu Kα radiation (λ = 1.54 Å) (Siemens, Karlsruhe, Germany) and a voltage 
of 40 mV in the angular range (2θ) varying from 10 to 60° using a step scan mode with a step 
size of 0.02° and a measuring time of 1 s/step. 
 
Adhesion 
 
The adhesion between core and coat was analyzed using a tensile tester with a load cell 
capacity of 100 N (LF Plus, Lloyd Instruments, West Sussex, UK). The co-extruded mini-
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matrices were placed on a metal disk with a central opening of 3.3 mm, above which the 
core of the co-extruded mini-matrices was positioned to make sure only the coat was 
supported by the device. A probe with a diameter of 2 mm was used to apply a downward 
force on the core (preload 1 N; extension rate 100 mm/min) and the maximum force needed 
to separate coat from core was measured. The test was repeated 10 times for each tested 
formulation.  
 
Raman spectroscopy 
 
The distribution of the different components in the coat and core of the co-extrudates was 
evaluated with Raman microscopic mapping using a Raman Rxn1 Microprobe (Kaiser Optical 
Systems Inc, Ann Arbor,  MI, USA), equipped with an air-cooled charge coupled device (CCD) 
detector. The laser wavelength employed was 785 nm from a Invictus near infrared (NIR) 
diode laser (Kaiser Optical Systems Inc, Ann Arbor,  MI, USA). All spectra were recorded with 
a resolution of 4 cm-1 and an exposure time of 2 s, using a laser power of 400 mW. Cross 
sections of co-extrudates were scanned by a 10 x long working distance objective lens in 
point-by-point mapping mode using a step size of 50 µm in both the x and y directions (18 x 
13 = 234 spectra per mapping). The resulting images provide information about the 
distribution of different components in the co-extrudates. Data collection and data transfer 
were automated using the HoloGRAMSTM data collection software (version 2.3.5, Kaiser 
Optical Systems Inc, Ann Arbor,  MI, USA), the HoloMAPTM data analysis software (version 
2.3.5, Kaiser Optical Systems Inc, Ann Arbor,  MI, USA) and Matlab® software (version 7.1, 
The MathWorks Inc., Natick, MA, USA). In order to correct for the uneven surface of the co-
extrudates, manually cut in half using a surgical blade, all spectra were preprocessed using 
Pearsons method to perform a baseline correction.  
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In order to attribute specific Raman peaks in the spectra to the different components in the 
formulations, Raman spectra were collected from the pure components and the physical 
mixtures. All spectra were recorded with a resolution of 4 cm-1 and an exposure time of 5 s. 
Standard normal variate (SNV) pre-processing was applied on the collected spectra prior to 
analysis, to correct for the variation in path length/sampling distance between probe and 
sample. 
 
Stability study 
 
A sufficient number of mini-matrices from the 3 different formulations was manufactured to 
perform a stability study. Immediately after co-extrusion, the formulations were filled in an 
amber glass container and stored in closed condition at 25 °C/60 %RH and in open condition 
at 40 °C/75 %RH. To investigate the influence of storage MDSC, XRD, and in vitro drug 
release were performed on the co-extrudates immediately after manufacturing, after 1 
month, 3 months and 6 months storage, respectively.  
 
In vivo evaluation 
 
Study design 
All procedures were performed after approval by the Ethics Committee of the Institute for 
Agricultural and Fisheries Research (ILVO) (Merelbeke, Belgium). To study the drug plasma 
profiles for hydrochlorothiazide and metoprolol tartrate, the formulations listed in Table 1 
were administered to 6 male mixed-breed dogs (23 - 41.5 kg). For the test formulations A, B, 
C and D the co-extruded mini-matrices were filled in hard-gelatin capsules, whereas the 
reference formulation was given as 2 tablets Zok-Zid® (Pfizer, Brussels, Belgium). During the 
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cross-over study the formulations were administered in randomized order, taking into 
account a wash-out period of at least 8 days. The dogs were fasted for 12 h prior to and after 
the administration of the formulations, but water was available ad libitum. At the start of the 
study an intravenous cannula was placed in the lateral saphenous and a blank blood sample 
was collected. The formulations were orally administered with 20 ml of water and blood 
samples were subsequently collected in dry heparinized tubes at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 
4, 5, 6, 8, 10 and 12 h after administration. The blood samples obtained were centrifuged for 
5 min at 1500 g within 1 h after collection. The plasma was separated and frozen at -20 °C 
before analysis. 
 
Metoprolol tartrate and hydrochlorothiazide assay 
Two different validated high performance liquid chromatography (HPLC) methods were used 
to determine metoprolol tartrate and hydrochlorothiazide plasma concentrations in the dog 
plasma. After extraction of metoprolol tartrate and the internal standard bisoprolol 
hemifumarate from the plasma using a solid phase extraction (SPE) procedure, with Oasis® 
MCX 1 cc (30 mg) cartridges (Waters, Brussels, Belgium), a HPLC method with fluorescence 
detection was used for the determination of metoprolol tartrate [13]. Hydrochlorothiazide 
was extracted from the plasma samples by means of a liquid-liquid extraction with the 
internal standard hydroflumethiazide and afterwards determined using a HPLC-UV method 
[14]. The HPLC system consisted of an isocratic solvent pump (L-7100, Merck, Hitachi 
LaChrom, Tokyo, Japan) and an automatic autosampler (L-2200, Merck, Hitachi Elite 
LaChrom, Tokyo, Japan). For the MPT analysis a guard column (LiChroCart® 4-4, LiChrospher® 
100 CN (5 µm), Merck, Darmstadt, Germany) followed by a reversed phase CN column 
(LiChroCart® 250-4, LiChrospher® 100 CN (5 µm), Merck, Darmstadt, Germany) and a 
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variable wavelength fluorescence detector (L-7480, Merck, Hitachi LaChrom, Tokyo, Japan) 
were used. The pump flow was set at 1.1 ml/min and the excitation and emission 
wavelength were 275 nm and 300 nm, respectively. For the HCT analysis a guard column 
(LiChroCart® 4-4, LiChrospher® 100 RP-18e (5 µm), Merck, Darmstadt, Germany) followed by 
a reversed phase column (LiChroCart® 250-4, LiChrospher® 100 RP-18 (5 µm), Merck, 
Darmstadt, Germany) and a UV-detector (L-7400, Merck, Hitachi LaChrom, Tokyo, Japan) 
were used. The pump flow was set at 0.8 ml/min and the detection wavelength was 272 nm. 
Since metoprolol tartrate did not cause an interfering peak during the determination of 
hydrochlorothiazide, and vice versa, the specificity of the methods was secured. Peak 
integration was performed using the software package D-7000 HSM Chromatography Data 
Station (Hitachi Instruments, San Jose, CA, USA).  
 
Data analysis 
The metoprolol tartrate and hydrochlorothiazide plasma concentrations were normalized for 
dose and body weight of the dogs, by dividing the respective plasma concentrations by dose 
per kg body weight for each dog. The peak plasma concentration (Cmax), the extent of 
absorption (AUC0-12h) and the time to reach the peak plasma concentration (tmax) were 
calculated. The controlled release characteristics of the core formulation were evaluated by 
means of the HVDt50%Cmax, defined as the width of the plasma concentration profile at 50% of 
the Cmax [15]. The bioavailability data were statistically evaluated using SPSS 17 (SPSS, 
Chicago, USA). To compare the effects of the different treatments on the pharmacokinetic 
parameters, a multiple comparison among pairs of means was performed using a Bonferroni 
post-hoc test with p < 0.05 as significance level. 
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RESULTS AND DISCUSSION  
 
Formulation and production of co-extrudates 
 
In order to produce a combination product with an immediate release coat and a controlled 
release core via co-extrusion some combinations of polymer-plasticizer mixtures were hot-
melt extruded and evaluated for their processability. A successful co-extrusion process 
requires that both polymer melts can be processed at similar temperatures, match in melt 
viscosity and show adequate adhesion. Therefore combinations of polymer-plasticizer 
mixtures for core and coat were tested. As a first combination Kollidon SR® was assessed for 
the controlled release core and Soluplus® for the immediate release coat. At a metoprolol 
tartrate load of 30 %, Kollidon SR® only slightly sustained the release (80 and 100 % released 
at 2 and 8 h, respectively). The addition of the hydrophobic plasticizer dibutyl sebacate (15 
%) only minimally improved the sustained release profile (with 80 and 100 % released at 4 
and 8 h, respectively). Soluplus® was initially assessed in combination with a wide range of 
plasticizers. The lowest possible extrusion temperature (130 °C) was reached for the 
formulation containing 10 % Lutrol F68®. This coat formulation only offered an immediate 
release profile for hydrochlorothiazide concentrations of 5 % or less. A second core/coat 
combination tested consisted of an ethylcellulose matrix for the controlled release core and 
a polyethylene oxide 100K/polyethylene glycol 4K immediate release coat. Dibutyl sebacate  
has previously been used to plasticize an ethylcellulose matrix and polyethylene 
glycol/polyethylene oxide was added in different concentrations to modify the metoprolol 
tartrate release [11, 16]. As a core matrix ethylcellulose, plasticized with dibutyl sebacate, 
sustained metoprolol tartrate release in an efficient way, but by adding a hydrophilic 
additive to this matrix it became possible to offer a range of release profiles for metoprolol 
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tartrate release. Polyethylene oxide 1M was selected as a hydrophilic additive and a design 
of experiments (DOE) methodology was employed to set up 11 experiments (8 experiments 
+ 3 center points) in a mixture design in order to extrude metoprolol tartrate at a drug load 
of 30 % in different combinations of ethylcellulose, dibutyl sebacate and polyethylene oxide 
1M as a matrix. Two formulations with a similar ethylcellulose/dibutyl sebacate ratio but a 
major difference in metoprolol tartrate release were finally selected. Both had a drug load of 
30 % metoprolol tartrate but a different matrix composition: (A) 53 % ethylcellulose + 27 % 
dibutyl sebacate + 20 % polyethylene oxide 1M and (B) 62 % ethylcellulose + 33 % dibutyl 
sebacate + 5 % polyethylene oxide 1M. In order to steer the metoprolol tartrate release not 
only by the amount of hydrophilic polymer (polyethylene oxide 1M) but also by drug load, 
this parameter was evaluated as a release-controlling factor as well. Therefore, a third 
formulation (C) was manufactured, containing 53 % ethylcellulose + 27 % dibutyl sebacate + 
20 % polyethylene oxide 1M with a drug load of 15 % metoprolol tartrate in the core. For the 
corresponding coat formulation polyethylene oxide 100K, which has previously been used as 
a carrier in hot-melt extrusion, was chosen as main component [17, 18]. To optimize this 
coat formulation different concentrations of polyethylene glycol 4K were added to 
polyethylene oxide 100K and the hydrochlorothiazide release was evaluated [6]. A 
concentration of 15 % polyethylene glycol 4K proved to be sufficient for immediate 
hydrochlorothiazide release and consistently yielded co-extrudates of good quality with a 
smooth surface and good adhesion between core and coat (Fig. 1). 
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Figure 1. Image of co-extrudate, before and after cutting into mini-matrices of 2 mm length. Core diameter 3 
mm and coat thickness 0.5 mm. 
 
Therefore 85 % polyethylene oxide 100K + 15 % polyethylene glycol 4K was selected as 
matrix for the coat with the drug load adjusted in order to obtain a final formulation with 
the same metoprolol tartrate : hydrochlorothiazide ratio as the reference formulation (8:1). 
The metoprolol tartrate-loaded plasticized ethylcellulose matrix, with the addition of 
polyethylene oxide 1M as a hydrophilic additive, was finally co-extruded with the 
hydrochlorothiazide-loaded polyethylene oxide 100K/polyethylene glycol 4K coat at a 
temperature of 100 °C. The obtained co-extrudates had a regular shape, a smooth surface, a 
white opaque inner layer and a transparent outer layer. 
 
In vitro drug release 
 
The influence of both the hydrophilic additive and the drug load on metoprolol tartrate 
release from the core is illustrated in Fig. 2.  
CHAPTER 1 – HOT-MELT CO-EXTRUSION FOR THE PRODUCTION OF FIXED-DOSE COMBINATION PRODUCTS 
WITH A CONTROLLED RELEASE ETHYLCELLULOSE MATRIX CORE 
59 
 
 
Figure 2. In vitro metoprolol tartrate release (in phosphate buffer pH 6.8) for formulation A ( ), formulation 
B ( ), formulation C ( ), reference ( ) and mean hydrochlorothiazide release (in 0.1 N HCl) for co-
extrudate A to C ( ). Mean (n = 3) dissolution profiles (± SD) of each co-extrudate and reference. Dissolution 
at 37 °C and 100 rpm. 
  
As previously reported the metoprolol tartrate release from the ethylcellulose matrix 
containing 20 % of polyethylene oxide 1M is diffusion controlled with a constant diffusion 
coefficient [19]. By reducing the amount of polyethylene oxide 1M in the matrix from 20 
(formulation A) to 5 % (formulation B) the metoprolol tartrate release was found to be 
delayed from 80 and 100 % after 2 and 8 h, respectively, in formulation A to 36, 60, 70 and 
90 % after 2, 8, 12 and 24 h, respectively, in formulation B. At this low polyethylene oxide 
1M concentration it has been described that the mobility of the high molecular weight 
polyethylene oxide is increased with increasing matrix porosity over time, leading to an 
metoprolol tartrate release approximating a zero-order release [19]. Reducing the 
polyethylene oxide concentration lowered the burst release to around 20 % for formulation 
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B. The same delaying effect on the in vitro metoprolol tartrate release profile was seen by 
lowering the drug load from 30 % (formulation A) to 15 % (formulation C). The reference 
formulation, where metoprolol tartrate is formulated in coated pellets which are 
compressed into tablets, has a slightly different release profile for metoprolol tartrate 
compared to the matrix formulations B and C, showing a slower release during the first 8 
hours and a lower burst release (8 % compared to 23 and 21 % for the matrix formulations B 
and C, respectively). For hydrochlorothiazide the immediate release criteria are met, with 
complete release obtained after 30 min for all formulations. 
  
Physical state characterization 
 
Fig. 3.a shows the MDSC thermograms of the core components, metoprolol tartrate, 
ethylcellulose : dibutyl sebacate physical mixture in a 2:1 ratio, polyethylene oxide 1M, the 
physical mixtures of a core formulation and the corresponding extruded formulation. 
Metoprolol tartrate showed a peak melting endotherm at 123.9 °C, while polyethylene oxide 
1M showed a peak melting temperature at 70.2 °C, indicating the crystalline state of these 
compounds. The reversing heat flow for the 2:1 ethylcellulose : dibutyl sebacate mixture 
showed a clear change in heat capacity in the temperature range from 34 to 48 °C with a 
glass transition (Tg) at 39.5 °C. The indication that the 2:1 ethylcellulose : dibutyl sebacate 
mixture is in an amorphous state was confirmed by XRD analysis. Thermal analysis of the 
physical mixture and the extruded core formulation revealed that metoprolol tartrate 
remained crystalline after hot-melt extrusion. Fig. 3.b shows the MDSC thermograms for the 
components of the coat, hydrochlorothiazide, the 85:15 polyethylene oxide 100K : 
polyethylene glycol 4K matrix, the physical mixture and the corresponding extrudate. 
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Hydrochlorothiazide showed a peak melting temperature at 267.2 °C, while the polyethylene 
oxide 100K/polyethylene glycol 4K matrix showed a peak endotherm at 66.2 °C, indicating 
the crystalline state of these compounds. Thermal analysis of the physical mixture and the 
extruded coat formulation revealed only a melting endotherm of the polyethylene oxide 
100K : polyethylene glycol 4K 85:15 matrix, indicating that hydrochlorothiazide is dissolved 
in the coat matrix. For the physical mixture this result is attributable to the heating of the 
sample during the MDSC experiment, where the small amount of hydrochlorothiazide in the 
physical mixture gradually dissolved in the molten polymer mixture during heating. 
 
 
 
Figure 3.a. MDSC thermograms of metoprolol tartrate (A), ethylcellulose : dibutyl sebacate 2:1 (B), 
polyethylene oxide 1M (C), physical mixture of 62% ethylcellulose + 33% dibutyl sebacate + 5% polyethylene 
oxide 1M with 30% metoprolol tartrate (D), extruded core formulation B: 62% ethylcellulose + 33% dibutyl 
sebacate + 5% polyethylene oxide 1M with 30% metoprolol tartrate (E).  
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Figure 3.b. MDSC thermograms of hydrochlorothiazide (A), physical mixture of 85% polyethylene oxide 100K + 
15% polyethylene glycol 4K (B), physical mixture of 85% polyethylene oxide 100K + 15% polyethylene glycol 4K 
with 5.6% hydrochlorothiazide (C), extruded coat formulation B: 85% polyethylene oxide 100K + 15% 
polyethylene glycol 4K with 5.6% hydrochlorothiazide (D).  
 
The physicochemical state was also characterized using XRD and Raman spectroscopy. The X-
ray diffraction patterns of the pure drug substances, the core and coat physical mixtures and 
the corresponding formulations are shown in Fig. 4. The X-ray diffractogram of metoprolol 
tartrate showed distinct diffraction peaks at 2θ of 10.7°, 16.0°, 19.6°, 20.5° and 23.3°. Since 
these peaks were also detected in the diffractogram of the physical mixture and the 
extruded core formulation, it can be concluded that the crystalline state of metoprolol 
tartrate was maintained in the hot-melt extrudates. The diffraction pattern of pure 
hydrochlorothiazide revealed several representative peaks, which also showed up in the 
diffractogram of the physical mixture of the coat. The absence of these peaks in the 
diffraction pattern of the extruded coat revealed that there were no hydrochlorothiazide 
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crystals left in the coat of the co-extrudate, confirming that hydrochlorothiazide was 
dissolved in the polyethylene oxide 100K : polyethylene glycol 4K 85:15 matrix after hot-melt 
extrusion.  
 
Figure 4. X-ray diffraction patterns of metoprolol tartrate (A), physical mixture core (B), co-extrudate core (C), 
hydrochlorothiazide (D), physical mixture coat (E), co-extrudate coat (F) for formulation A.  
 
These results were confirmed with Raman spectroscopy. Raman peaks attributed to 
metoprolol tartrate, detected in the core of the co-extrudate, remained as sharp as in the 
physical mixture, indicating that metoprolol tartrate stayed in its crystalline state and the 
extrusion process did not affect the solid state of the metoprolol tartrate (Fig. 5).  
 
Figure 5. Selected regions of the Raman spectra of metoprolol tartrate, physical mixture of core and core of the 
co-extrudate for formulation B.  
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From the selected region of the Raman spectra in Fig. 6 it can be concluded that the Raman 
peaks attributed to hydrochlorothiazide in the coat of the co-extrudate showed broadening 
and a lower intensity when compared to the physical mixture, indicating the loss of 
crystallinity for hydrochlorothiazide. 
 
 
Figure 6. Selected region of the Raman spectra of hydrochlorothiazide, physical mixture of the coat and coat of 
the co-extrudate for formulation B. (Left scale for the selected region of the pure HCT spectrum. Right scale for 
the selected region of the spectra for physical mixture of the coat and co-extrudate of the coat.) 
  
Co-extrudate characterization 
 
The microscopic image of the co-extrudate clearly showed the two distinct layers, properly 
attached to each other. An adhesion test was performed in order to measure the adhesion 
force between core and coat. For the formulation with ethylcellulose 62 % + dibutyl sebacate 
33 % + polyethylene oxide 5 % as a core matrix (formulation B), loaded with 30 % metoprolol 
tartrate the average force needed to detach the core from the coat was 8.3 ± 2.6 N. The 
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mini-matrices also passed a friability test (< 0.1 % weight loss), without any signs of 
detachment between core and coat layers.  
To evaluate the distribution of the drug products in core and coat, Raman microscopic 
mapping was performed. The peak intensity of the Raman band of metoprolol tartrate in the 
810 - 830 cm-1 region was monitored to map the distribution of metoprolol tartrate in the 
core and to check if there was diffusion of metoprolol tartrate in the coat. Fig. 7 shows the 
distribution of metoprolol tartrate, throughout different sections of the co-extruded 
core/coat formulation. A red color corresponds to a high peak intensity, indicating a high 
metoprolol tartrate concentration, while a blue color corresponds to a low metoprolol 
tartrate concentration. The metoprolol tartrate band in the 810 - 830 cm-1 region showed an 
intense peak in the core but not in the coat. The peak intensity of the Raman band of 
hydrochlorothiazide in the 700 - 720 cm-1 region was monitored to map the distribution of 
hydrochlorothiazide in the coat and to check if diffusion of hydrochlorothiazide in the core of 
the co-extrudate had occurred during hot-melt extrusion. The hydrochlorothiazide band in 
the 700 - 720 cm-1 region showed an intense peak in the coat but not in the core, indicating 
no intermigration of core and coat drug components during processing, given the spatial 
resolution of 50 µm. 
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Figure 7. Raman mapping of metoprolol tartrate in two sections of the co-extrudate containing 30% metoprolol 
tartrate in the core. A red color corresponds to a high peak intensity in the 810 - 830 cm
-1 
region, indicating the 
presence of metoprolol tartrate. A blue color corresponds to a very low peak intensity, indicating absence of 
metoprolol tartrate.  
 
Physical stability 
 
Stability issues when using polyethylene oxide as a main matrix former in hot-melt extrusion 
have been reported previously. Polymer degradation of polyethylene oxide when stored 
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below its melting point was occurring more rapidly for the lower molecular weight polymer 
in comparison to the higher molecular weight polyethylene oxide and is due to oxygen 
permeation in the amorphous region of the semi-crystalline polymer [17]. Therefore, 
influences of storage conditions on drug release were investigated for the co-extruded 
formulations. 
The co-extrudates of the three different formulations (A, B and C) kept their original shape 
and integrity during the entire stability study. The influence of storage on metoprolol 
tartrate release for formulation B is shown in Fig. 8. The same observations were made for 
hydrochlorothiazide release during the stability study. For both drugs the overall release 
profile remains similar over time and in both storage conditions. 
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Figure 8. In vitro metoprolol tartrate (MPT) release (in phosphate buffer pH 6.8) for co-extrudate formulation B 
(Core: 62% ethylcellulose + 33% dibutyl sebacate + 5% polyethylene oxide 1M with 30% metoprolol tartrate), 
initially ( ) and after storage for 1 month at 25°C/60%RH ( ) and 40°C/75%RH ( ), 3 months at 
25°C/60%RH ( ) and 40°C/75%RH ( ) and 6 months at 25°C/60%RH ( ) and 40°C/75%RH ( ). Mean 
(n = 3) dissolution profiles (± SD) of co-extrudates. Dissolution at 37 °C and 100 rpm. 
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MDSC-profiles for the core extrudates after 1 and 3 months at different storage conditions 
indicated the stability of the crystalline state of the metoprolol tartrate fraction incorporated 
in the core. To evaluate the physical stability of the coat the X-ray patterns of the 5.6 % 
hydrochlorothiazide formulation stored during 3 months at different storage conditions 
were compared with the X-ray pattern of the physical mixture and of the pure drug (Fig. 9).  
The diffraction patterns of the 3 months stability samples were similar with the formulation 
immediately after processing and indicated that hydrochlorothiazide stayed dissolved in the 
coat after 3 months at both conditions. 
 
 
 
Figure 9. X-ray diffraction patterns of hydrochlorothiazide (A), physical mixture coat (B), coat co-extrudate after 
3 months storage at 25°C/60%RH (C) and coat co-extrudate after 3 months storage at 40°C/75%RH (D) for 
formulation A. 
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In vivo evaluation 
 
To study the hydrochlorothiazide and metoprolol tartrate bioavailability, co-extrudates 
(formulation A, B, C and D) were administered to 6 dogs. The bioavailability was compared 
with a commercially available reference formulation, Zok-Zid®, a tablet containing 
hydrochlorothiazide and coated metoprolol tartrate pellets. The mean normalized plasma 
concentration-time profiles (n = 6) for hydrochlorothiazide and metoprolol tartrate after oral 
administration of formulation A, B, C (25 mg hydrochlorothiazide and 200 mg metoprolol 
tartrate), formulation D (25 mg hydrochlorothiazide and 100 mg metoprolol tartrate) and 
the reference (2 tablets) are illustrated in Fig. 10 and Fig. 11, respectively, while the mean 
pharmacokinetic parameters (AUC, Cmax, tmax and HVDt50%Cmax) are reported in Table 2 and 
Table 3, respectively. The drug plasma concentration profiles confirmed the in vitro 
dissolution results. The immediate in vitro hydrochlorothiazide release from the coat was 
confirmed in vivo with a Tmax value of about 2 hours for all co-extrudates. The rather fast in 
vitro metoprolol tartrate release from formulation A was reflected in the in vivo study since 
this formulation showed a burst release with a mean Cmax of 26.6 ng/ml obtained after 2.8 h, 
compared with a Cmax of 12.8 ng/ml and 12.3 ng/ml obtained after 3.1 h and 3.5 h after 
administration of formulation B and C, respectively. The high metoprolol tartrate plasma 
concentrations reached after administration of the co-extruded matrix formulations in 
comparison to the reference formulation, were indicating that the administered MPT dose 
could be reduced. Therefore, Formulation D was designed with the same core composition 
as formulation B in combination with a coat having a higher HCT load to be able to half the 
MPT dose while maintaining the HCT dose for administration to dogs. The pharmacokinetic 
parameters (AUC and Cmax) of this formulation were not different at the 0.05 level of 
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significance from the reference formulation. Moreover, similar to formulation B and C, 
formulation D was characterized by a HVDt50%Cmax of more than 7 h, illustrating better 
controlled release characteristics than the reference formulation with a HVDt50%Cmax of 4.8 h. 
The difference in pharmacokinetic parameters for metoprolol tartrate between the co-
extruded matrix formulations and the coated pellet reference formulation, as already 
noticed in the in vitro results, can be observed clearly in vivo, where a lag phase of 2 hours is 
seen for the reference formulation. This might be attributed to the hydrophobic 
ethylcellulose coating of the pellets in comparison to the mini-matrices, causing metoprolol 
tartrate only to be released further down the gastrointestinal tract (GIT) and thus missing 
the absorption sites in the dogs small intestine. It has been documented that dogs have an 
unsacculated colon and therefore handle the transit of fluid and small particles in a fast way 
[20]. In contrast to the small pellets in the reference formulation it can be assumed that the 
larger mini-matrices are retained at the ileocecal junction, increasing the residence time in 
the ileum which offers a better absorption of the metoprolol tartrate, since it has been 
demonstrated previously that metoprolol is absorbed to the same degree from the 
duodenum and colon [21]. It has been demonstrated that for metoprolol tartrate the co-
extruded matrix formulations offer a higher bioavailability in dogs (AUC 3 to 7-fold higher 
and Cmax 2 to 7-fold higher) than the reference pellet formulation. From the dog plasma 
concentrations it can be concluded that the metoprolol tartrate dose administered with 
formulation D could even be halved. 
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Figure 10. Mean (n = 6) hydrochlorothiazide (HCT) plasma concentration-time profiles after oral administration 
of the co-extruded formulations A ( ), B ( ), C ( ), D ( ) 
 (25 mg hydrochlorothiazide) and Zok-Zid® tablets ( ) (2 tablets) to dogs.  
The SD for formulation A and B are shown, for the other formulations SD is of the same magnitude.   
 
 
 
HCT AUC0-12h (µg.h/ml) Cmax (µg/ml) Tmax (h) 
Co-extrudate A 1,3 ± 0,4
a,b
 0,3 ± 0,1
a
 2,3 ± 0,9 
Co-extrudate B 1,6 ± 0,5
a,b
 0,4 ± 0,1
a,b
 1,9 ± 0,6 
Co-extrudate C 1,3 ± 0,2
a
 0,3 ± 0,0
a
 2,5 ± 1,0 
Co-extrudate D 2,0 ± 0,3
b
 0,5 ± 0,2
a,b
 1,9 ± 1,0 
Reference 2,0 ± 0,2
b
 0,6 ± 0,1
b
 2,5 ± 1,1 
a, b: means in the same column with the same superscript are not different  
at the 0.05 level of significance. 
 
Table 2. Mean (n = 6) pharmacokinetic parameters (± SD) after oral administration of the co-extruded 
formulations A, B, C, D (25 mg hydrochlorothiazide) and Zok-Zid® tablets (2 tablets) to dogs. 
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Figure 11. Mean (n = 6) metoprolol tartrate (MPT) plasma concentration-time profiles after oral administration 
of the co-extruded formulations A ( ), B ( ), C ( ) (200 mg metoprolol tartrate) and D ( ) (100 
mg metoprolol tartrate) and Zok-Zid® tablets ( ) (2 tablets) to dogs. The SD for formulation A and B are 
shown, for the other formulations SD is of the same magnitude. 
 
 
 
MPT AUC0-12h (ng.h/ml) Cmax (ng/ml) Tmax (h) HVDt50%Cmax (h) 
Co-extrudate A 134,7 ± 43,2c 26,6 ± 9,2d 2,8 ± 0,8 4,4 
Co-extrudate B 88,9 ± 35,0a,b,c 12,8 ± 5,6a,c 3,1 ± 0,9 8 
Co-extrudate C 85,0 ± 18,2b,c 12,3 ± 3,6b,c,d 3,5 ± 0,5 7,8 
Co-extrudate D 53,6 ± 11,0a,b 7,4 ± 2,0a,b 4,5 ± 3,9 >11,4 
Reference 18,3 ± 14,7a 3,8 ± 3,3a 4,7 ± 2,0 4,8 
            a, b, c, d: means in the same column with the same superscript are not different at the 0.05  
              level of significance. 
 
Table 3. Mean (n = 6) pharmacokinetic parameters (± SD) after oral administration of the co-extruded 
formulations A, B, C (200 mg metoprolol tartrate) and D (100 mg metoprolol tartrate) and Zok-Zid® tablets (2 
tablets) to dogs. 
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Mathematical modeling 
 
A new mathematical model was developed to predict the drug plasma profiles as a function 
of the observed in vitro drug release kinetics, taking into account: (a) metoprolol tartrate 
transport within the controlled release dosage form and (b) drug fate in vivo. The theoretical 
predictions were compared with independent experimental results. The rational of the 
mathematical theory is as follows: Drug release from the ethylcellulose matrix was described 
using a mechanistically realistic theory, assuming that drug diffusion in the cylinders is the 
dominant mass transport step (Fig. 12). Considering perfect sink conditions, an initial 
homogeneous drug and polymer distribution and unaltered device dimensions during drug 
release, Fick’s second law of diffusion can be solved using the method of Laplace 
transformation, leading to [22]: 
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where Mt and M∞ denote the cumulative amounts of drug released at time t and at infinite 
time, respectively; D is the diffusion coefficient of the drug within the system; the qn are the 
roots of the Bessel function of the first kind of zero-order [J0(qn)=0]; n and p denote dummy 
variables, and R and H represent the radius and height of the cylinder, respectively. 
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Figure 12. Radial and axial diffusional drug transport in the cylindrical dosage form, considered in the 
mathematical model. 
 
Fitting this equation to the experimentally measured metoprolol tartrate release kinetics 
from different types of formulations resulted in good agreement between theory (curves in 
Fig. 13) and experiment (symbols in Fig. 13). 
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Figure 13. Theoretical predictions (curves) and independent experimental results (symbols) of in vitro 
metoprolol tartrate release for formulation A (blue, ▲), formulation C (green, ●) and formulation D (red, ■). 
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The model assumes that in vitro drug release is identical to drug release within the 
gastrointestinal tract, the dosage form being robust and controlling drug release in the same 
manner in the different surroundings. 
Once released the drug is available for absorption into the blood stream. An open one-
compartment model is assumed, with first order absorption and first order elimination 
kinetics (Fig. 14). 
 
 
 
Figure 14. Schematic representation of the processes taken into account by the applied mathematical model, 
considering drug release in the gastrointestinal tract (GIT), drug absorption into the blood stream and drug 
elimination. 
 
 
The following parameters of metoprolol were taken from literature:  
(i) absorption rate constant reported in humans for a “fast releasing formulation” 
(0.85 1/h) [23],  
(ii) volume of distribution/bioavailability factor reported in humans for a “fast 
releasing formulation” (638 L) [23],  
(iii) elimination rate constant reported in beagle dogs (0.4 1/h) [24].  
The mathematical model was solved numerically, using the programming language C++. Fig. 
15 shows a comparison of the resulting metoprolol tartrate plasma profiles: the curves 
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represent the theoretically predicted pharmacokinetics, the symbols the independent 
experimental results (Fig. 15). 
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Figure 15. Theoretical predictions (curves) and independent experimental results (symbols) of metoprolol 
tartrate plasma profiles for formulation A (blue, ▲), formulation C (green, ●) and formulation D (red, ■). 
 
 
The good agreement between theoretical predictions and independent experimental results 
indicated that the developed mathematical model is applicable and that the resulting in vivo 
drug plasma levels can be predicted based on in vitro release kinetics. This can reduce the 
number of in vivo studies required for product optimization. 
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CONCLUSION 
 
In this chapter we have demonstrated that fixed-dose combination mini-matrices with a 
matrix core offering a range of controlled release profiles and an immediate release coat 
were successfully developed by co-extrusion. The mini-matrices showed good adhesion and 
no migration of active drug substances between core and coat. Metoprolol tartrate release 
from the ethylcellulose matrix core could be sustained in function of the drug load and the 
content of the hydrophilic additive. High metoprolol tartrate plasma concentrations were 
obtained after oral administration to dogs, which indicated that the MPT dose could be 
lowered to achieve the same bioavailability compared to a commercial reference 
formulation. However this advantage in dose reduction should be confirmed in humans. A 
stability study indicated that the co-extrudates were stable for at least 6 months at different 
storage conditions. From this study it can be concluded that co-extrusion proved to be a 
valuable technique for the production of oral FDC drug products with multiple release 
profiles. Moreover the featured tests provided a thorough physical characterization of the 
co-extrudates manufactured. Interestingly, an appropriate mathematical model (taking into 
account drug transport within the controlled release dosage form and the in vivo fate of 
metoprolol tartrate) was able to predict the resulting drug plasma levels, based on the in 
vitro release kinetics and parameters reported in the literature. The theoretical predictions 
agreed well with independent experimental results. Thus, the number of in vivo studies 
required for product optimisation can be reduced. 
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ABSTRACT 
 
In this chapter calendering is used as a downstream technique to shape monolithic co-
extruded fixed-dose combination products in a continuous way. Co-extrudates with a 
metoprolol tartrate-loaded sustained-release core and a hydrochlorothiazide-loaded 
immediate-release coat were produced and immediately shaped into a monolithic drug 
delivery system via calendering, using chilled rolls with tablet-shaped cavities. In vitro 
metoprolol tartrate release from the ethylcellulose core of the calendered tablets was 
prolonged in comparison to the sustained release of a multiparticulate dosage form, 
prepared manually by cutting co-extrudates into mini-matrices. Analysis of the dosage forms 
using X-ray micro-computed tomography only detected small differences between the pore 
structure of the core of the calendered tablet and the mini-matrices. Diffusion path length 
was shown to be the main mechanism behind the release kinetics. Terahertz pulsed imaging 
visualized that adhesion between the core and coat of the calendered tablet was not 
complete and a gradient in coat thickness (varying from 200 to 600 µm) was observed. 
Modulated differential scanning calorimetry and X-ray diffraction indicated that the 
physicochemical properties of both drugs were not affected by the calendering procedure. 
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INTRODUCTION 
 
In co-extrusion two or more formulations are simultaneously processed via hot-melt 
extrusion (HME) through the same die. In addition to the advantages of HME, such as the 
continuity of the production process, not requiring the use of solvents or water and 
improving drug bioavailability, this technique offers the opportunity to produce fixed-dose 
combination (FDC) products with enhanced release characteristics, by making it possible to 
design multilayered dosage forms that are extruded in the same process step, in order to 
modulate the drug release from each layer. Although co-extrusion is used to manufacture 
implants [1] and vaginal rings [2], there are currently no co-extruded dosage forms for oral 
application on the market. In the literature only a limited number of studies describe co-
extrusion of dosage forms for oral drug delivery [3-6]. Recently co-extrusion has been used 
for the development of multiparticulate fixed-dose combination drug products for oral 
pharmaceutical application, consisting of a controlled release core matrix and an immediate 
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release coat [7]. For pharmaceutical applications of co-extrusion, one of the major 
challenges is the shaping of the final product in a continuous way, as a suitable downstream 
shaping technique is needed to ensure an efficient manufacturing line. Previously injection 
molding has been used to shape extrudates into solid oral dosage forms in a semi-
continuous way [8, 9] and even to prepare co-injection moulded matrices [4]. Calendering is 
a technique that allows in-line shaping of the extruded material in a fully continuous single-
step process. Using this technique the freshly-extruded thermoplastic strand is guided 
through a pair of temperature-controlled rolls containing tablet- or pill-shaped cavities, 
yielding strips that contain single tablet-shaped cores of the desired shape. Although this 
technique is already widely established in the plastic and confectionary industry to produce 
monolithic shapes, only the Meltrex® technology [10] and the continuous extrusion process 
for the production of sustained release tablets developed by Knoll AG [11] report 
calendering as a possible shaping tool for pharmaceutical applications.  
In this study the use of calendering to continuously shape a multilayered co-extrudate into a 
monolithic FDC dosage form was evaluated. In the treatment of cardiovascular disease the 
FDC of the beta-blocker metoprolol tartrate (MPT) with the diuretic hydrochlorothiazide 
(HCT) is well established [12]. Therefore co-extrudates consisting of a plasticized 
ethylcellulose (EC) core, containing MPT and polyethylene oxide (PEO), and a coat of 
polyethylene oxide (PEO)/polyethylene glycol (PEG) containing HCT were produced. 
Afterwards the cylindrical co-extrudate with concentric coat layer was immediately shaped 
via calendering, using chilled rolls with tablet-shaped cavities. In this way monolithic dosage 
forms with a sustained-release core, loaded with MPT as model drug, and an immediate-
release coat, loaded with HCT as model drug, were produced and evaluated for in vitro drug 
release, coat thickness and uniformity and pore structure. The impact of the calendering 
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step on the physical state of the drugs in the formulations was characterized using 
modulated differential scanning calorimetry (MDSC) and X-ray diffraction (XRD). 
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MATERIALS AND METHODS 
 
Materials 
 
Metoprolol tartrate (MPT) (Esteve Quimica, Barcelona, Spain) and hydrochlorothiazide 
(HCT) (Utag, Amsterdam, the Netherlands) were used as sustained and immediate release 
model drugs, respectively. As excipients ethylcellulose (EC) (Ethocel® std 10, Colorcon, 
Dartford Kent, United Kingdom), dibutyl sebacate (DBS) (Sigma-Aldrich, Bornem, Belgium), 
polyethylene oxide (PEO) 1M (MW: 1000000 g/mol, SentryTM Polyox® WSR N12K, Colorcon, 
Dartford Kent, United Kingdom), PEO 100K (MW: 100000 g/mol, SentryTM Polyox® WSR N10, 
Colorcon, Dartford Kent, United Kingdom) and polyethylene glycol (PEG) 4K (MW: 4000 
g/mol, Fagron, Waregem, Belgium) were used.  All other chemicals were of analytical grade. 
 
Hot-melt co-extrusion 
 
Co-extrusion was carried out using two co-rotating Prism Eurolab 16 mm twin screw 
extruders (ThermoFisher Scientific, Karlsruhe, Germany), connected to a co-extrusion die 
(Guill, West Warwick, USA). In the calendering set-up the co-extrusion die was adapted to fit 
the diameter of the co-extrudate with the dimensions of the calender cavities, shaping a 
cylindrical co-extrudate consisting of a core with a diameter of 4 mm and a concentric coat 
with a thickness of 2 mm. To produce the multiparticulates, a cylindrical co-extrudate with 
an inner diameter of 3 mm and an outer diameter of 4 mm was manufactured. The heating 
zones of both extruders were heated to 80/90/100/100/100/100 °C from feed opening to 
die-end. The co-extrusion die was heated to 100 °C. Both premixes were fed separately into 
an extruder by a Brabender Flexwall® loss-in-weight powder feeder (Brabender, Duisburg, 
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Germany) at a feed rate of 200 g/h for the coat and 300 g/h for the core material. A screw 
speed of 40 rpm and 150 rpm was used for the extruder producing the outer layer and the 
inner layer, respectively. 
 
Downstream processing 
 
Calendering was performed with a Collin 60 mm calender (Dr. Collin, Ebersberg, Germany), 
coupled to a compressed air supply and a Coolenergy chiller (Plastima, Breda, The 
Netherlands), which cooled the calender rolls to a temperature within the range of 4-8 °C. 
The speed of the calender rolls was set at 1.5 rpm. Immediately after leaving the co-
extrusion die the co-extruded strand was guided between a pair of chilled pressurized rolls 
that contained tablet-shaped cavities, yielding tablets with a diameter of 8 mm and a 
thickness of 5 mm (cfr. Fig. 5 page 22).  
To test the effect of cooling on the MPT release a core extrudate was prepared using the 
same process parameters as for the core in the co-extrudate. Part of this material was 
cooled at room temperature, while the remaining part was quench-cooled by dipping the 
core extrudate in liquid nitrogen immediately after extrusion. 
Multiparticulates were obtained by manually cutting a cylindrical co-extrudate with an inner 
diameter of 3 mm and an outer diameter of 4 mm into mini-matrices of 2 mm length after 
cooling the co-extruded rod to room temperature. 
 
In vitro drug release 
 
In vitro dissolution was performed using United States Pharmacopeia (USP) dissolution 
apparatus 1 (baskets) on an Evolution 6300 dissolution system (Distek, New Brunswick, New 
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Jersey, USA), coupled with an Evolution 4300 automatic dissolution sampler (Distek, New 
Brunswick, New Jersey, USA). The temperature of the dissolution medium (900 ml) was kept 
at 37 ± 0.5 °C and the rotational speed of the baskets was set to 100 rpm. For the first hour 
a 0.1 N solution of hydrochloric acid (pH 1) was used as the dissolution medium. Afterwards 
the baskets containing the mini-matrices or tablets were transferred to vessels filled with 
phosphate buffer pH 6.8 (USP) as the dissolution medium. Samples (filtered using Distek 45 
µm filters) of 5 ml were withdrawn at 5, 10, 15, 20, 30, 45 and 60 minutes for the 
determination of HCT concentration in the first dissolution medium and at 1, 2, 4, 6, 8, 12, 
16, 20 and 24 hours for the determination of MPT concentration in the second dissolution 
medium. The core layer was analyzed separately to cover for the MPT release during the 
first hour. Samples were analyzed spectrophotometrically at 316.6 and 222.0 nm, using a 
UV-spectrophotometer, type UV-1800 (Shimadzu, Deurne, Belgium) and applying an 
appropriate calibration curve for quantification of HCT and MPT, respectively. Each 
experiment was performed in triplicate. 
 
Modulated differential scanning calorimetry 
 
The solubility of HCT in the coat of the tablet was studied by cyclic heating of an 
oversaturated sample, containing 70 % HCT, followed by annealing at a different 
temperature for each cycle in order to reach the maximum solubility at each temperature. 
After the annealing step the sample was quenched and heated again to determine the glass 
transition temperature (Tg). These cycles were performed for different annealing 
temperatures in between the melting point of polymer matrix and drug, and the shift in Tg 
was monitored using a differential scanning calorimeter Q200, equipped with a refrigerated 
cooling system (RCS) (TA Instruments, Leatherhead, UK). Nitrogen was used as purge gas 
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through the DSC cell (50 ml/min) and the RCS unit (300 ml/min). Samples (± 3 mg) were run 
in an open aluminum pan with an underlying heating rate of 5 °C/min. The modulation 
period and amplitude were set at 50 s and 0.663 °C, respectively (heat-only method). 
Temperature and enthalpy calibration was performed with an indium standard at the same 
scan rate and with the same kind of pans used in the experiment. MDSC data were analyzed 
using the TA instruments Universal Analysis 2000 V4.7A software. 
 
X-ray diffraction 
 
Crystallinity was analyzed using X-ray diffraction (XRD) on pure compounds, physical 
mixtures and corresponding extrudates. X-ray diffraction was performed on a D5000 
diffractor with Cu Kα radiation (λ = 1.54 Å) (Siemens, Karlsruhe, Germany) and a voltage of 
40 mV in the angular range (2θ) varying from 10 to 60 ° using a step scan mode with a step 
size of 0.02 ° and a measuring time of 1 s/step. 
 
Terahertz pulsed imaging 
 
The calendered tablets from different formulations were analyzed using a terahertz pulsed 
imaging (TPI) imaga2000 coating scan system (Teraview, Cambridge, UK). The operation of 
this system was previously described by Zeitler et al. [13]. Images were acquired in a point-
to-point mode with a step size of 200 µm. Images were analyzed using TPI View (version 
3.0.3, Teraview, Cambridge, UK). A six-axis robot arm was used to produce a surface map of 
the calendered tablet. The refractive index of the coating material was estimated to be 1.5, 
based on the surface reflectivity of the calendered tablets as well as by calibration using X-
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ray micro-computed tomography. Given the very smooth texture of the surface this was 
deemed to represent an appropriate measurement for the refractive index as no surface 
scattering would contribute to the losses. Using this value histograms and maps of coating 
uniformity were plotted using Matlab (R2013a, The Mathworks, Natick MA, USA). 
 
X-ray micro-computed tomography 
 
The porosity of the mini-matrices and tablets was evaluated by means of X-ray micro-
computed tomography (micro-CT). Co-extruded mini-matrices and calendered tablets were 
scanned using a Skyscan 1172 high resolution X-ray micro-CT system (Bruker microCT, 
Kontich, Belgium), operated at 59 kV source voltage, with an image pixel size of 1.37 µm and 
4.53 µm, for the mini-matrix and the tablet, respectively. The scanning system is equipped 
with an aluminum 0.5 mm filter and an 11 Mp charge coupled device (CCD) detector. For 
the scan with the image pixel size of 4.53 µm the samples were rotated over 0.4 ° steps, 
exposure time was 1000 ms and total scan duration was 42 min. For the high resolution 
offset-scan the samples were rotated over 0.2 ° steps, exposure time was 2350 ms, frame 
averaging was 5 and total scan duration was 9 h 17 min. The images were reconstructed 
with NRecon (Version 1.6.3.2, Bruker microCT, Kontich, Belgium) on a GPU-ReconServer. A 
Gaussian smoothing kernel of 2 pixels was applied, resulting in an 8-bit bitmap (BMP) image 
with a linear X-ray attenuation coefficient, displayed as a grey scale value calibrated 
between 0 and 255. To compare both dosage forms at the same pixel size, the images of the 
mini-matrix system were resized fourfold prior to analysis. Data analysis and visualization 
was done with CTAn software (version 1.13.5.1, Bruker microCT, Kontich, Belgium) and 
CTVol (version 2.2, Bruker microCT, Kontich, Belgium) for surface rendering. For image 
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analysis the core was defined as the region of interest (ROI). To this end, applying a 
Gaussian blur by 2 pixels allowed separating the two peaks in the grey scale histogram with 
a threshold of 34. Pixels with lower intensities were assigned to the core and pixels with a 
higher intensity were assigned to the coat layer. This ROI is applied to the original greyscale 
images, in this way removing the coat. Greyscale images were binarised using an Otsu-
algorithm, one of the most popular techniques of automatic thresholding [14]. 3D objects 
smaller than 20 voxels were considered to be noise and were filtered out of the image used 
for porosity analysis. A distinction is made between internal pores, which are located in the 
core of the co-extrudate, and pores at the interface between core and coat. The percentage 
of internal pores is quantified as the ratio between the internal pore volume in the core and 
the object volume (i.e. total volume of solid core material, excluding pores). The percentage 
of pores at the interface between both layers is defined as the ratio between the pore 
volume at the interface and the total core volume (i.e. region of interest volume, including 
pores). A size distribution of the pores is illustrating the percentage of pores in a certain 
range of structure thickness. Local structure thickness for a point in solid material is defined 
by Hildebrand and Ruegsegger as the diameter of the largest sphere that encloses the point 
and is entirely enclosed within the solid surfaces [15]. 
 
 
CHAPTER 2 – CALENDERING AS A DIRECT SHAPING TOOL FOR THE CONTINUOUS PRODUCTION OF FIXED-DOSE 
COMBINATION PRODUCTS VIA CO-EXTRUSION 
92 
 
RESULTS AND DISCUSSION  
 
In order to continuously shape a multilayered co-extrudate into a final monolithic FDC 
tablet-shaped dosage form the co-extrusion line was extended downstream with a calender 
and chiller. Although calendering has been used previously to shape an extrudate into a final 
dosage form [10, 11], to our knowledge this study is the first to evaluate calendering as a 
downstream tool in a co-extrusion process, thus producing a dosage form with an outer 
layer that is surrounding the inner core. In order to evaluate the effect of calendering on the 
release profiles of two model drugs, formulations with a MPT-loaded sustained release core 
and a HCT-loaded immediate release coat were used (Table 1): the two core formulations A 
and B varied in their EC/PEO ratio while a lower MPT content was used in formulation C. 
This allowed to evaluate the effect of calendering as a function of the concentration of PEO 
(added as hydrophilic additive) and the MPT load [16]. The composition of the coat 
formulation was constant, except for the HCT load of formulation C that was adjusted in 
order to respect the same MPT/HCT ratio in each of the co-extruded formulations. 
 
 Matrix Drug load 
Formulation A Core 53% EC 27% DBS 20% PEO 1M 30% MPT 
Coat 85% PEO100K  15% PEG 4K 5.6% HCT 
Formulation B Core 62% EC 33% DBS 5% PEO 1M 30% MPT 
Coat 85% PEO100K  15% PEG 4K 5.6% HCT 
Formulation C Core 53% EC 27% DBS 20% PEO 1M 15% MPT 
Coat 85% PEO100K  15% PEG 4K 2.8% HCT 
Table 1. Composition of calendered formulations A, B and C. 
 
The MPT-loaded plasticized EC matrix (with the addition of PEO 1M as a hydrophilic 
additive) was co-extruded with its HCT-loaded PEO 100K/PEG 4K coat at a temperature of 
100 °C. The inserts of the co-extrusion die were adapted to match the dimensions of the co-
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extrudate with the dimensions of the calender cavities. The co-extruded string was guided 
between the chilled calender rolls to shape a string of tablets. Calendered tablets were 
regular in shape and had a uniform aspect as long as the calender rolls were chilled at 4 ± 1 
°C. When the chiller did not succeed in adequately cooling the calender rolls (i.e. using a chill 
water temperature > 6°C), the calendered tablets deformed when the calendered string 
detached from the calender rolls. As aspect defects were found to be highly dependent on 
calender speed and temperature, a low calender speed was used to allow adequate cooling 
and perfect shaping of the calendered tablets [17]. The cooling rate of the material between 
the calender rolls seemed essential to obtain a dosage form with good shape and uniform 
dimensions (Fig. 1).  
 
 
Figure 1. Cross-section (left) and side-view (right) of a calendered tablet, with a sustained release core and an 
immediate release coat. 
 
 
Although minimized by adjusting the die dimensions to the dimensions of the calender 
cavities, waste material was created at the sides of the tablets when forcing the co-extruded 
strand in between the calender rolls. The amount of waste was 7.5 % w/w of the total 
weight of the co-extruded calendered material. As this waste at the edges of the tablets 
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must be removed to obtain the final dosage forms, this is especially a disadvantage when 
working with highly valuable active ingredients. Based on the drug content of the waste 
material, it was assessed that it is mainly composed of coat material (93 % of the total waste 
fraction), while only a minor part of core material is lost during calendering. This should be 
taken into account as this yields tablets with a higher MPT/HCT ratio than theoretically 
anticipated based on coat and core composition. The higher MPT/HCT ratio was confirmed 
by quantification of the MPT and HCT concentration in the calendered tablets: a ratio of 
8.58 vs. 8.00 based on the composition of coat and core layer. Since TPI was previously used 
for the non-destructive analysis of coated tablets [18] this technique was used to visualize 
the coat layer and to study the adhesion between core and coat. Especially interesting for 
the analysis of calendered tablets via TPI is the fact that not only the thickness of the coat 
layer, but also the uniformity and integrity of the coat can be analyzed, since penetration 
depths into typical pharmaceutical formulations between 1 and 3 mm can currently be 
achieved [13]. The thickness of the coat layer varied between 200 and 600 µm (Fig. 2).  
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Figure 2. False-colour images, showing spatial distribution, and histograms of coating thickness for coat layer 
and for the air gap between core and coat layer, of the calendered tablet formulation B, analyzed both at top 
and bottom of the tablet. 
 
 
In the false-colour images of the tablets of formulation B, a thickness gradient in the coat 
layer is observed (Fig. 2), which is more pronounced at the top face compared to the bottom 
face of the calendered tablets. This gradient can be explained by the sequenced contact of 
different regions of the tablet with the calender rolls. The cross section images based on the 
micro-CT data from a string of tablets confirmed this by revealing a recurrent pattern of the 
thinner area in the coating layer (Fig. 3).  
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Figure 3. Micro-CT image of a string of calendered tablets, where the recurrent thinner part of the coat layer is 
indicated with an arrow and detail of the calendered tablet for formulation B. 
 
The analysis of the calendered tablet via TPI also clearly identified that the adhesion 
between core and coat was not complete as an air gap at the interface between both 
extruded layers was detected (Fig. 2). The incomplete adhesion was also confirmed by 
micro-CT (Fig. 3) and quantified as the percentage of pores at the intersection of core and 
coat. These pores at the intersection of core and coat for calendered tablets (2.37 %) were 
also found for the multiparticulates (2.06 %), indicating that the incomplete adhesion 
between coat and core was not linked to the calendering step in the process, but originated 
during the co-extrudate formation. These air pockets could become entrapped between 
 
Core 
 Coat: thick part 
Coat : thin part 
Incomplete adhesion  
Incomplete adhesion  
1000 µm 
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coat and core layer when both extrusion flows merge, or could be due to different shrinking 
characteristics of both polymer layers upon cooling. The air gap between the coating and 
the core is unlikely to have any influence on the release characteristics for a tablet with an 
immediate release coat (as manufactured in this study) since the coat will rapidly dissolve 
and expose the core to the dissolution medium. However, the results show that calendering 
as a post-processing step for co-extruded formulations needs further optimization for drug 
delivery systems where the coat controls the release of the core, as the differences in 
thickness of the coating layer and incomplete adhesion between both layers observed in 
this study would induce significant variability in the release rate. Moreover, for those types 
of systems it will be challenging to obtain a coat that completely seals the core, a feat that is 
difficult to achieve with the calendering set-up used in this study, especially at the edges of 
the calendered tablets (Fig. 3).  
Physicochemical characterisation of MPT and HCT in core and coat, respectively, was 
performed in order to evaluate the effect of calendering on the physical state of the 
incorporated drug substances. The solubility of HCT in the PEO/PEG carrier was determined 
by monitoring the shift in Tg after annealing a supersaturated physical mixture at different 
temperatures and subsequent quenching. First of all the Gordon-Taylor curve was 
established for different mixtures of HCT in the PEO/PEG carrier. The composition 
dependence of the glass transition temperature was fitted by the usual Gordon-Taylor law 
[19, 20]: 
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In equation 1 Tg(HCT) and Tg(carrier) are respectively the glass transition temperature of pure 
HCT and the carrier, X(HCT) is the HCT fraction in the mixture, and K is a fitting parameter 
characterizing the curvature of the evolution.  
In order to determine the drug concentration dissolved in the polymer carrier at each 
annealing temperature the Tg values from the annealing experiment were plotted on the 
Gordon-Taylor curve. In this way the solubility curve was determined (Fig. 4). The 
concentration of HCT (5.6 % w/w) in the coat layer of the tablet was far below the solubility 
limit (31 % w/w) of HCT in the carrier.  
 
 
Figure 4. Evolution of glass transition temperature, fitted with a Gordon-Taylor law (●) and solubility curve (♦) 
for HCT in the PEO/PEG carrier.  
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This was confirmed by the absence of the melting endotherm of HCT in the MDSC 
thermogram and by the absence of any peaks representative of crystalline HCT in the X-ray 
diffraction pattern of the extruded coat, demonstrating HCT was present in the coat as a 
solid solution in the semi-crystalline polymer mixture. MDSC thermograms of MPT-loaded 
core formulations showed a melting peak at 118 °C. The enthalpy of fusion indicated that 
the main drug fraction remained crystalline in the calendered tablets: 82.3 and 85.0 % MPT 
was in a crystalline state in the core of formulations A and B, respectively. Similar values of 
MPT crystallinity were detected in the core of the mini-matrices (80.0 and 85.8 % for 
formulations A and B, respectively), indicating that the calendering step did not affect the 
solid state properties of MPT. The X-ray diffraction pattern of the core of the calendered 
tablet also revealed diffraction peaks of MPT, confirming that the crystalline state of MPT 
was at least partially maintained in the tablets. Moreover, the X-ray diffractogram did not 
reveal differences between the cores of calendered tablets and co-extruded mini-matrices. 
The pore structure of the core in both dosage forms, calendered tablets and mini-matrices, 
was compared using micro-CT. The percentage of internal pores was 4.00 % and 1.08 % for 
the core of the mini-matrices and calendered tablets, respectively. The lower amount of 
internal pores in the calendered tablet can be attributed to the additional densification of 
the material during calendering. In addition, the internal pores in the calendered tablet 
were smaller in size: an average structure thickness of 17 ± 20 µm, in comparison to 83 ± 5 
µm for the mini-matrix (Fig. 5).  
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Figure 5. Pore size distributions of internal pores for mini-matrix (■) and calendered tablet (●), analyzed on a 
reconstructed micro-CT image. 
 
 
However, these limited differences in number and size of the internal pore structure are 
unlikely to have an impact on drug release. The difference in sustained release of MPT 
between the monolithic calendered tablets and the multiparticulates is illustrated in Fig. 6. 
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Figure 6.a. In vitro MPT release (in phosphate buffer pH 6.8) from mini-matrices (●) and calendered tablet (■) 
for formulation A. Mean (n = 3) dissolution profiles (± SD) of co-extrudates. 
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Figure 6.b. In vitro MPT release (in phosphate buffer pH 6.8) from mini-matrices (●) and calendered tablet (■) 
for formulation B. Mean (n = 3) dissolution profiles (± SD) of co-extrudates. 
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The MPT burst release was reduced by half for all calendered formulations in comparison 
with the mini-matrices. Moreover, the monolithic calendered tablet sustained MPT release 
to a larger extent than the mini-matrices, with a complete release after only 24 h instead of 
8 h in case of formulation A. The lower mass transport rates from the calendered tablets 
were linked to the dimensions of the dosage forms: the core of the calendered tablet had a 
diameter of 7 mm and a thickness of 4 mm, whereas the core of the mini-matrices had a 
diameter of 3 mm and a length of 2 mm. The importance of relative surface area available 
highlighted the importance of diffusion path length for MPT dissolution from the matrices 
and was confirmed by performing dissolution tests on cylindrical extrudates with a similar 
surface area/volume ratio to the calendered tablet and on a central part of the calendered 
tablet with the same dimensions as the mini-matrices. Both test set-ups indicated that the 
diffusion path length is the main contributor for the differences in release profiles observed 
between the calendered tablets and the multiparticulate formulation. Based on the release 
data it is evident that manufacturing an easily swallowable tablet-shaped monolithic dosage 
form offered an advantage over the multiparticulate formulation for sustained drug release. 
For the calendered formulation B, with 5 % PEO and 30 % drug content, MPT release after 
48 h was only 75 %. In contrast, complete drug release from formulation C (containing 20 % 
PEO and 15 % MPT) was obtained after 48 h (Fig. 7a). These differences in release profiles 
indicated that PEO was the main contributor for drug release. Because of the smaller 
dimensions of the mini-matrices, the matrix effect was of lesser importance for MPT release 
from the multiparticulates (Fig. 7b). The type of dosage form did not influence the 
immediate release profile of HCT, with a complete release within 45 min for all 
formulations.  
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Figure 7.a. In vitro MPT release (in phosphate buffer pH 6.8) from calendered tablets for formulation A  (●), 
formulation B (■), formulation C (▲). Mean (n = 3) dissolution profiles (± SD) of co-extrudates. 
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Figure 7.b. In vitro MPT release (in phosphate buffer pH 6.8) from mini-matrices for formulation A  (●), 
formulation B (■), formulation C (▲). Mean (n = 3) dissolution profiles (± SD) of co-extrudates. 
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To assess the impact of cooling during calendering (essential to avoid sticking of the dosage 
form to the rolls), the effect of the cooling rate on MPT release from the calendered tablets 
was determined. Cooling was performed via quench-cooling in liquid nitrogen or via cooling 
at room temperature. However, the MPT release profiles were independent of the cooling 
technique. Moreover, X-ray diffractograms of the extrudates of formulations A and B 
demonstrated that cooling rate did not affect crystallinity of MPT in these formulations (Fig. 
8). 
 
 
Figure 8. X-ray diffraction patterns of MPT (1), extruded core formulation B cooled at room temperature (2) or 
quench-cooled in liquid nitrogen (3), extruded core formulation A cooled at room temperature (4) or quench-
cooled in liquid nitrogen (5). 
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CONCLUSION 
 
In this study we have demonstrated that calendering is a promising downstream processing 
step to continuously produce tablet-shaped monolithic FDC dosage forms from multilayered 
matrix co-extrudates. With the calendered tablet an in vitro MPT release was sustained over 
24 to 48 h, in combination with an immediate HCT release from the coat. The differences in 
diffusion path length of the final monolithic tablet-shaped dosage form mainly determined 
the MPT release from the core. Calendering and cooling did not affect the sustained MPT 
release profiles. A limited reduction of the porosity of the core after calendering indicated 
some additional densification of the material during calendering. The shaping technique did 
not alter the physicochemical state of the drugs. Further characterization using TPI revealed 
a gradient in coat thickness and incomplete adhesion between core and coat, the latter 
being inherent to the co-extrudate and independent of the calendering step, as visualized by 
micro-CT. 
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ABSTRACT 
 
This study aimed to design a fixed-dose combination dosage form which provides a 
sustained release profile for both the freely water-soluble metformin HCl and the poorly 
soluble gliclazide, two anti-diabetic compounds used to treat diabetes mellitus, using co-
extrusion as manufacturing technique. Developing a matrix formulation that sustained 
metformin release is challenging, given that its high dose requires a high drug load in the 
formulation and that the drug is freely soluble. From this study it was clear that co-extrusion 
of a coat layer, containing at least 30 % CAPA® 6506 as a hydrophobic polymer, was 
necessary to adequately sustain the release of the highly dosed freely soluble drug from the 
70 % metformin HCl-loaded CAPA® 6506 core of the co-extrudate. To obtain a complete 
release over 24 h for gliclazide solubilization in Kollidon® VA, added as a second polymer to 
the CAPA® 6506 in the coat, was needed. In this way both active pharmaceutical ingredients 
(API’s), which have different physicochemical characteristics, were formulated in a single 
dosage form, which is composed of two separate layers, each demonstrating adequate 
properties for the incorporated API. 
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INTRODUCTION 
 
Hot-melt extrusion (HME) has found its way to pharmaceutical industry for the production 
of drug-loaded matrix formulations because of its advantages over conventional techniques, 
such as the possibility to improve drug solubility or sustain drug release via a continuous 
production process. HME has been used to produce medical devices for several decades and 
is now being used in pharmaceutical industry for the development of drug delivery systems 
like transdermal patches and solid dosage forms. Co-extrusion is defined as the 
simultaneous extrusion of two or more materials creating a multilayered extrudate [1]. This 
highly efficient continuous manufacturing technique is designed to produce fixed-dose 
combination products but still has to find its way into pharmaceutical production. Dierickx 
et al. used co-extrusion to produce multilayered mini-matrices for oral drug delivery [2]. Co-
extrusion has more recently been used to produce fixed-dose combination mini-matrices 
with a matrix core offering a range of controlled release profiles and an immediate release 
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coat [3], and to produce a solid dosage form which provides dual release of a single drug [4]. 
The aim of this study was to manufacture a dosage form with a drug-loaded coat, sustaining 
not only the release of the poorly soluble drug incorporated in the coat but also that of a 
high-dosed freely water-soluble drug incorporated in the core - using co-extrusion as a 
continuous production process.  
The freely water-soluble metformin HCl and the poorly soluble gliclazide were used as 
model compounds for the development of a co-extruded concentric core/coat fixed-dose 
combination (FDC) product. Both are anti-diabetic compounds used to treat diabetes 
mellitus type 2, a complex endocrine and metabolic disorder with increasing prevalence [5]. 
In the treatment of patients with type 2 diabetes mellitus it has been demonstrated that 
combination therapy is more likely to achieve glucose control than monotherapy [6]. The 
most commonly used pharmacological agent as a first-line treatment in newly diagnosed 
patients is metformin. Sulphonylurea agents, such as gliclazide, are the most frequently 
used add-on treatment [7]. The combination of metformin with sulfonylurea agents such as 
gliclazide is commonly used and has proven to bring additive effects and an acceptable side 
effect profile [8, 9]. A fixed-dose combination product of metformin and gliclazide has 
proven to be beneficial since it can improve convenience and adherence to the prescribed 
therapy and to contribute to better blood glucose control [10].  
Formulating metformin as a sustained release dosage form is beneficial to address issues of 
gastrointestinal (GI) intolerability, with up to 25 % of the patients describing some degree of 
GI upset leading to cessation of the therapy in 5 - 10 % of patients [11], and to avoid 
multiple daily dosing leading to reduced adherence [12]. It has been shown that patients 
that were switched from immediate release (IR) metformin to a once-daily extended release 
(ER) metformin formulation (Glucophage® ER) experienced fewer GI side effects although 
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the mean daily metformin dose was similar [13, 14]. Gliclazide modified release was 
previously formulated in a hypromellose-based matrix and 30 mg given once-daily showed 
similar efficacy and tolerability to gliclazide immediate release 80 mg/day [15]. A 
progressive release of the short-acting gliclazide can maintain therapeutic levels throughout 
the day [16]. Therefore this study aimed to design a dosage form which provides a sustained 
release profile for both compounds. Using co-extrusion as manufacturing technique both 
API’s, which have different physicochemical characteristics, are formulated in a single 
dosage form, since the co-extruded material was composed of two separate layers, each 
demonstrating adequate properties for sustained release of the incorporated API. 
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MATERIALS AND METHODS 
 
Materials 
 
Metformin HCl (Fagron, Waregem, Belgium) was used as a high dose freely water-soluble 
drug in combination with gliclazide (Eurolabs limited, Congleton, UK). Metformin HCl and 
gliclazide were incorporated in the core and coat, respectively, of the co-extruded dosage 
form. The following materials were evaluated as excipients for the core matrix formulation: 
polycaprolactone with different MW: 50000 g/mol (CAPA® 6506, Perstorp, Warrington, UK), 
80000 g/mol (CAPA® 6800, Perstorp, Warrington, UK) and 124000 g/mol (Purasorb® PC12, 
Corbion Purac Biomaterials, Gorinchem, The Netherlands), ethylcellulose (Ethocel® std 10, 
Colorcon, Dartford Kent, United Kingdom), dibutyl sebacate (Sigma-Aldrich, Bornem, 
Belgium), polyethylene glycol 4K (PEG 4K, MW: 4000 g/mol, Fagron, Waregem, Belgium), 
poloxamer 188 (Lutrol® F68, BASF, Ludwigshafen, Germany), a 8:2 blend of polyvinyl acetate 
and polyvinylpyrrolidone (Kollidon® SR, BASF, Ludwigshafen, Germany), low-density 
polyethylene (LDPE, SABIC, Riyadh, Saudi Arabia). For the coat formulation polycaprolactone 
with a MW of 50000 g/mol (CAPA® 6506, Perstorp, Warrington, UK) and copovidone 
(Kollidon® VA 64, BASF, Ludwigshafen, Germany) were used as excipients. All other 
chemicals used were of analytical grade. 
 
Hot-melt extrusion and co-extrusion 
 
In a first phase hot-melt extrusion was performed to select an appropriate polymer matrix 
for the highly metformin HCl-loaded core extrudate, using a co-rotating Prism Eurolab 16 
mm fully intermeshing twin screw extruder (ThermoFisher Scientific, Karlsruhe, Germany) 
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connected to a cylindrical die having a diameter of 4 mm (Guill, West Warwick, USA). For 
the core formulations the processing temperatures are given in Table 1. Premixes of drug, 
polymer and additives were fed into the extruder using a Brabender Flexwall® loss-in-weight 
powder feeder (Brabender, Duisburg, Germany) at a feed rate of 300 g/h for the core 
material. A screw speed of 20 rpm was used for the extruder. To compare release from core 
extrudates formulated with different polymer matrices the extrudate was manually cut in 
mini-matrices of 2 mm length. 
In a second phase co-extrusion was carried out using two co-rotating Prism Eurolab 16 mm 
twin screw extruders (ThermoFisher Scientific, Karlsruhe, Germany), both connected to the 
co-extrusion die (Guill, West Warwick, USA). A cylindrical co-extrudate with a core diameter 
of 4 mm and a concentric coat with a thickness of 1 mm (total co-extrudate diameter: 6 
mm) was manufactured. The zones of the barrel of the extruders producing the core and the 
coat were heated from feed opening to die-end to 90/100/120/110/110/110 and 
100/110/110/110/110/120 °C, respectively. The co-extrusion die was heated to 130 °C. The 
core and coat premix were fed separately into an extruder using a Brabender Flexwall® loss-
in-weight powder feeder (Brabender, Duisburg, Germany) at a feed rate of 250 g/h for the 
coat and 300 g/h for the core material. A screw speed of 20 rpm was used for both 
extruders. After cooling the cylindrical co-extrudate was manually cut into tablets of 5 or 10 
mm length. 
 
In vitro drug release 
 
In vitro dissolution was performed using United States Pharmacopeia (USP) dissolution 
apparatus 2 (paddles) on an Evolution 6300 dissolution system (Distek, New Brunswick, New 
Jersey, USA), coupled with an Evolution 4300 automatic dissolution sampler (Distek, New 
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Brunswick, New Jersey, USA). The temperature of the dissolution medium (900 ml) was kept 
at 37 ± 0.5 °C and the rotational speed of the paddles was set to 100 rpm. Phosphate buffer 
pH 6.8 or pH 7.4 (USP) was used as the dissolution medium. Samples (filtered using Distek 
45 µm filters) of 5 ml were withdrawn at 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 hours for the 
determination of the concentration of both compounds in the dissolution medium. For the 
initial experiments with the coat formulation an acetate buffer pH 4.1 was used since this is 
a more discriminative pH to test the solubility improvement of gliclazide, which has a pH-
dependent solubility [17]. In these experiments samples (filtered using Distek 45 µm filters) 
of 5 ml were withdrawn at 5, 10, 20, 30, 45, 60 and 120 min. Samples were analyzed 
spectrophotometrically at 232.8 nm and 226.4 nm, using a UV-spectrophotometer (UV-
1800, Shimadzu, Deurne, Belgium) and applying an appropriate calibration curve for 
quantification of metformin and gliclazide, respectively. Each experiment was performed in 
triplicate. 
 
Modulated differential scanning calorimetry  
 
The crystallinity of the drug in the matrices and the thermal behavior of pure compounds, 
physical mixtures and corresponding extrudates were studied using a differential scanning 
calorimeter Q2000 V24.8 equipped with a refrigerated cooling system (TA Instruments, 
Leatherhead, UK). Nitrogen was used as purge gas through the DSC cell (50 ml/min) and the 
refrigerated cooling system (RCS) unit (300 ml/min). Samples (± 5 mg) were run in 
hermetically closed Tzero pans with perforated lid, supplied by TA Instruments, with an 
underlying heating rate of 2 °C/min. The modulation period and amplitude were set at 60 s 
and 0.318 °C, respectively. Mass of sample pan and empty reference pan were taken into 
account. Temperature and enthalpy calibration was performed with an indium standard, 
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whereas calibration of the heat capacity was performed using a sapphire standard. 
Modulated differential scanning calorimetry (MDSC) data were analyzed using the TA 
instruments Universal Analysis 2000 V4.7A software. Melting enthalpies were determined in 
the total heat flow signal. Melting temperatures were reported as peak temperatures. 
Degree of crystallinity was calculated based on melting enthalpy of the drug in the extruded 
formulation compared to the pure drug. 
 
X-ray diffraction  
 
Crystallinity was analyzed using X-ray diffraction (XRD) on pure compounds, physical 
mixtures and corresponding extrudates. X-ray diffraction was performed on a D5000 
diffractometer with Cu Kα radiation (λ = 1.54 Å) (Siemens, Karlsruhe, Germany) and a 
voltage of 40 mV in the angular range (2θ) varying from 10 to 60 ° using a step scan mode 
with a step size of 0.02 ° and a measuring time of 1 s/step. 
 
Adhesion 
 
The adhesion between core and coat was analyzed using a tensile tester with a load cell 
capacity of 100 N (LF Plus, Lloyd Instruments, West Sussex, UK). Co-extruded mini-matrices 
of 2 mm in length were placed on a metal disk with a central opening of 4.2 mm, above 
which the core of the co-extruded mini-matrices was positioned to make sure that only the 
coat was supported by the device. A probe with a diameter of 2 mm was used to apply a 
downward force on the core (preload 1 N; extension rate 100 mm/min) and the maximum 
force needed to separate coat from core was measured. The test was repeated 10 times, 
mean result and standard deviation are reported. 
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RESULTS AND DISCUSSION 
 
Developing a matrix formulation that sustained metformin release is challenging, given that 
its high dose requires a high drug load in the formulation and that the drug is freely soluble. 
In order to obtain a sustained release profile for metformin, several thermoplastic polymers 
were hot-melt extruded and evaluated for processability, macroscopic properties and in 
vitro drug release from mini-matrices with a length of 2 mm (Table 1).  
 
Matrix 
formulation 
Metformin 
HCl load 
Extrusion temperature (°C) 
From feed opening to die-end 
Torque
* 
Macroscopic 
properties 
Duration (h) to 
100 % release 
EC + 33% DBS 60 % 100/120/120/120/120/120/120 24 % Moderate 12 h 
EC + 33% DBS 70 % 100/150/150/150/150/150/150 20 % Inacceptable / 
Kollidon® SR 50 % 150/170/170/170/170/150/150 90 % Inacceptable / 
Kollidon® SR + 
10% Lutrol® F68 
70 % 150/175/175/175/175/150/150 67 % Good 4 h 
Kollidon® SR + 
20% Lutrol® F68 
70 % 140/165/165/165/165/140/140 65 % Good 2 h 
LDPE 70 % 100/100/100/100/100/100/100 25 % Good 2 h 
LDPE + 10% PEG 4K 70 % 110/110/110/110/110/110/110 15 % Good 2 h 
LDPE + 20% PEG 4K 70 % 95/95/95/95/95/95/95 30 % Good 2 h 
CAPA® 6506 60 % 60/60/60/60/60/60/60 89 % Good 4 h 
CAPA® 6506 70 % 80/80/80/80/80/80/80 75 % Good / 
*Torque in % of max value (12Nm/shaft). 
Table 1. Evaluation of processability, macroscopic properties and in vitro drug release from mini-matrices 
(length 2 mm) during a polymer screening of metformin HCl-loaded core formulations.  
 
Ethylcellulose (EC) could efficiently sustain metformin release over 12 h from EC-based 
formulations containing 60 % metformin HCl. However, at the required extrusion conditions 
(120 and 150 °C for a 60 and 70 % metformin HCl formulation, respectively) extrudates with 
a highly irregular shape which easily pulverized were formed, even as EC was combined with 
dibutyl sebacate (DBS) as plasticizer (EC : DBS ratio of 2:1). The higher extrusion 
temperature even resulted in a brown discoloration of the extruded EC-based samples. 
Using Kollidon® SR as matrix former resulted in a too high torque, even at a process 
temperature of 170 °C for a 50 % metformin HCl formulation. Inclusion of Lutrol® F68 
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improved the processability and the appearance of the metformin/Kollidon® SR extrudates: 
the addition of 10 and 20 % Lutrol® F68 as a plasticizer allowed to increase drug load to 70 
%, yielding smooth extrudates at a process temperature of 175 and 165 °C, respectively. 
However, the sustained release capacity of these formulations was limited: complete drug 
release after 4 and 2 h from formulations with a plasticizer content of 10 and 20 %, 
respectively. Similarly sustained metformin release from an LDPE matrix was limited at a 70 
% drug content: complete release after 2 h. In addition, the surface of these extrudates was 
irregular, even after the addition of PEG 4K as plasiticizer. Using CAPA® 6506 as a matrix 
polymer, mixtures with 60 % metformin HCl could be processed at a temperature of 60 °C, 
yielding solid extrudates with a regular shape and smooth surface. Even at a drug load of 70 
% the CAPA® 6506 matrix could be processed via hot-melt extrusion at a temperature of 
only 80 °C. Since these CAPA® 6506 matrices had a good appearance and could be 
manufactured at a low temperature, polycaprolactone was selected for further use. A 
metformin HCl content of 70 % was the maximum drug load possible: since 90 % of the drug 
remained crystalline, higher drug loadings were impossible to process into high-quality core 
extrudates. Subsequently the effect of polycaprolactone grades with different molecular 
weight on the release profile was tested (all formulations were processed at a temperature 
of 100 °C in all zones of the extruder). The entire drug content was released after 4 h from a 
60 % metformin HCl extrudate formulated with CAPA® 6506, while polycaprolactones with a 
higher molecular weight could sustain metformin release over 8 h. None of the 
polycaprolactone grades could sustain the metformin release from a highly drug-loaded 
extrudate over 24 h.  
Since a drug load of at least 60 % was essential to obtain a viable dosage form, a layer of 
CAPA® 6506, with a thickness of 1 mm, was applied around the core via a co-extrusion 
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process to reduce the metformin release rate. This strategy allowed to sustain drug release 
over a longer period, even a reduction of the length of the dosage form from 10 to 5 mm 
was needed to release the entire drug fraction within a 24 h period (Fig. 1).  
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Figure 1. Influence of the length of the co-extruded dosage forms on in vitro metformin HCl release: 5 (●) and 
10 mm (■). The CAPA® 6506 core of the co-extruded dosage form contained 60 % metformin HCl, while the 
coat consisted of pure CAPA® 6506. Mean (n=3) dissolution profiles (± SD), dissolution at 37 °C and 100 rpm in 
phosphate buffer pH 6.8. 
 
In addition to sustaining the release of metformin from the core, the coat layer also needed 
to sustain the release of gliclazide, the drug incorporated in the coat. When formulating 1.2 
% gliclazide in CAPA® 6506 only 29 % of the gliclazide content was released after 24 h in a 
pH 4.1 acetate buffer. Hence solubilization of the drug was indispensable to achieve 
complete gliclazide release. Since the potential of Kollidon® VA 64 to improve the solubility 
of poorly water-soluble drugs by manufacturing a solid dispersion via hot-melt extrusion has 
previously been shown [18, 19], mixtures of 1.2 and 10 % gliclazide in Kollidon® VA 64 were 
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hot-melt extruded. Both formulations yielded a transparent extrudate and the in vitro 
gliclazide release in pH 4.1 acetate buffer was complete after 20 min. This indicated that 
Kollidon® VA 64 was an efficient solubilizer for gliclazide in the CAPA® 6506 coat 
formulation, the latter polymer being an essential ingredient to sustain metformin release 
from the core. When combining CAPA® 6506 with Kollidon® VA 64 via hot-melt extrusion, 
both polymers formed a separate phase in the extrudate as thermal analysis revealed a 
CAPA® 6506 melting endotherm at 57.4 °C and a glass transition of Kollidon® VA 64 at 108.0 
°C. Gliclazide release from a coat formulation containing 5 % drug depended on the 
Kollidon® VA 64 : CAPA® 6506 ratio, a 55:40 ratio providing complete and sustained drug 
release over 24 h (Fig. 2).  
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Figure 2. Influence of Kollidon® VA 64 : CAPA® 6506 ratio on the in vitro gliclazide release from the coat of co-
extruded dosage forms: 65:30 (●), 55:40 (■) and 45:50 (▲) Kollidon® VA 64 : CAPA® 6506 ratio. The co-
extruded dosage form contained 5 % gliclazide in its coat, while the core consisted of pure CAPA® 6506. Mean 
(n=3) dissolution profiles (± SD), dissolution at 37 °C and 100 rpm in phosphate buffer pH 6.8.  
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The in vitro metformin release profiles from co-extrudates with a 70 % metformin HCl-
loaded CAPA® 6506 core and a coat with different Kollidon® VA 64 : CAPA® 6506 ratios 
(ranging from 60:40 to 80:20) indicated that a CAPA® 6506 concentration of at least 30 % 
was needed in the coat to sufficiently sustain metformin release over 24 h from the core of 
the co-extrudate (Fig. 3). Based on these results a Kollidon® VA 64 : CAPA® 6506 ratio of 
55:40 was selected as matrix composition for the coat layer in the co-extruded formulation.  
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Figure 3. Influence of Kollidon® VA 64 : CAPA® 6506 ratio on the in vitro metformin HCl release from the core 
of co-extruded dosage forms: 60:40 (●), 70:30 (■) and 80:20 (▲) Kollidon® VA 64 : CAPA® 6506 ratio. The co-
extruded dosage form contained 70 % metformin HCl in its CAPA® 6506 core, combined with a placebo 
Kollidon® VA 64 and CAPA® 6506 coat. Mean (n=3) dissolution profiles (± SD), dissolution at 37 °C and 100 rpm 
in phosphate buffer pH 6.8. 
 
For the final co-extruded dosage form, having a metformin HCl load of 70 % in the core and 
a CAPA® 6506 concentration of 40 % in the coat, metformin release from the core was 
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following zero-order kinetics. Gliclazide release from the coat was sustained over 24 h with 
a substantial burst release (25.5 % after 0.5 h) (Fig. 4). 
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Figure 4. In vitro metformin HCl (●) and gliclazide (■) release from co-extruded dosage forms. The core of the 
co-extruded dosage form contained  70 % metformin HCl + 30 % CAPA® 6506, while the coat was formulated 
with 5 % gliclazide, 55 % Kollidon® VA 64 and 40 % CAPA® 6506. Mean (n=3) dissolution profiles (± SD), 
dissolution at 37 °C and 100 rpm in phosphate buffer pH 6.8. 
 
The physicochemical state of both active compounds in the final co-extruded formulation 
was characterized using XRD and MDSC. The gliclazide peaks which were detected in the 
diffractogram of the physical mixture of the coat, were absent from the diffraction pattern 
of the extruded coat (Fig. 5). These results pointed out that gliclazide was present in 
dissolved state in the coat of the co-extrudate. MDSC analysis also indicated that gliclazide 
was solubilized in the amorphous Kollidon® VA 64 phase in the formulation. In contrast, 
after extrusion 90 % of the metformin HCl fraction (melting endotherm at 221.3 °C) 
remained crystalline in the CAPA® 6506 matrix (Fig. 6). 
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Figure 5. X-ray diffraction patterns of (from bottom to top): gliclazide (A), Kollidon® VA 64 (B), CAPA® 6506 (C), 
physical mixture of the coat formulation containing 5 % gliclazide (D) and extruded coat with the same 
composition (E). 
 
 
Figure 6. MDSC thermograms of (from top to bottom): metformin HCl (A), CAPA® 6506 (B), physical mixture of 
the core formulation containing 70 % metformin HCl and 30 % CAPA® 6506 (C) and extruded core with the 
same composition (D). 
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In order to characterize the degree of adhesion between both layers of the co-extrudate the 
adhesion force between core and coat was measured. For the final formulation the 
adhesion test revealed that the average force needed to detach the core from the coat was 
65.6 ± 10.9 N. This high value can be attributed to the fact that CAPA® 6506 was used in 
both core and coat, ensuring a high degree of interaction between both layers. 
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CONCLUSION 
 
Bilayer dosage forms containing an anti-diabetic drug in both core and coat were 
successfully developed by co-extrusion, offering a fixed-dose combination product 
sustaining the release over 24 h for both metformin HCl and gliclazide. A coat layer with at 
least 30 % CAPA® 6506 as a hydrophobic polymer was essential to adequately sustain 
metformin release from the CAPA® 6506 core of the co-extruded dosage form. Inclusion of 
Kollidon® VA 64 in the coat ensured complete release over 24 h of gliclazide via 
solubilization of the drug in the Kollidon® VA 64 phase. 
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ABSTRACT 
 
In this study hot-melt co-extrusion is used as a processing technique to manufacture a fixed-
dose combination product providing enteric protection to naproxen incorporated in the core 
and immediate release to esomeprazole magnesium embedded in the coat. Both core and 
coat were first independently developed. The plasticizing effect of naproxen and triethyl 
citrate (TEC) was tested on the enteric polymers investigated (Eudragit® L100-55, HPMC-AS-
LF and HPMCP-HP-50). Core matrix formulations containing HPMC-AS-LF, TEC and a 
naproxen load of 15, 30 and 50 % were processed and characterized. The in vitro naproxen 
release in 0.1 N HCl was prevented for 2 h for all formulations. The physicochemical state of 
the drug in the extrudates was determined and a stability study was performed. 
Intermolecular interactions between naproxen and polymer were identified using 
attenuated total reflection Fourier-transform infrared (ATR FT-IR) spectroscopy. 
Esomeprazole magnesium was formulated in an immediate release polymer, separated from 
the naproxen-containing enteric layer. When esomeprazole magnesium was formulated in a 
polyethylene oxide 100K : polyethylene glycol 4K (1:1) matrix, the formulation could be 
easily processed (lower torque) and complete in vitro drug release was observed after 45 
min. When co-extruding the core/coat dosage form it was observed that a third layer of 
polymer, separating the naproxen-loaded enteric formulation in the core from the coat, is 
required to prevent degradation of the acid-labile esomeprazole magnesium at the 
core/coat interface. 
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INTRODUCTION 
 
Hot-melt co-extrusion is defined as the simultaneous hot-melt extrusion of two or more 
materials creating a multilayered extrudate [1]. This continuous manufacturing technique 
still has to break through in pharmaceutical production, although several literature reports 
are already available on the use of co-extrusion for oral drug delivery. Quintavalle et al. were 
the first to produce cylindrical co-extrudates with controlled drug release via hot-melt 
extrusion, using polyethylene glycol as hydrophilic matrix and stearic acid or microcrystalline 
wax as hydrophobic matrix [2, 3]. Co-extruded mini-matrices have recently been formulated 
using core/coat technology with drugs incorporated in different polymer matrices in order to 
steer the release of different drugs [4, 5] or to provide a dual release of a single drug [6]. Co-
extrusion offers the potential to formulate fixed-dose combination products containing two 
chemically incompatible drugs in separate layers. 
The present study investigated if hot-melt co-extrusion allowed to manufacture a fixed-dose 
combination product providing enteric protection to the active pharmaceutical ingredient 
(API) incorporated in the core and immediate release to the API embedded in the coat. 
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Several enteric polymers were tested as core matrix former in combination with naproxen. 
This non-steroidal anti-inflammatory drug (NSAID) was used as a model drug. Since gastro-
protective co-therapy using a proton pump inhibitor is recommended to decrease the 
incidence of NSAID-related adverse events, esomeprazole magnesium was incorporated in 
the coat [7, 8]. Esomeprazole magnesium was formulated in a separate non-enteric polymer 
layer providing immediate drug release, which is essential to achieve rapid absorption of 
esomeprazole [9]. For both the core and coat layers different polymers were tested and their 
influence on release, physicochemical state characteristics and stability was monitored. 
Finally it was evaluated if co-extrusion of a core/coat dosage form allowed to formulate the 
two chemically incompatible API’s in a fixed-dose combination that offered the desired 
release profile for both API’s [8]. 
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MATERIALS AND METHODS 
 
Materials 
 
Naproxen (pKa 4.15) (Fagron, Waregem, Belgium) and esomeprazole magnesium trihydrate 
(Nifty labs, Hyderabad, India) were chosen as model drugs. Vimovo® (AstraZeneca, Brussels, 
Belgium), containing 500 mg enteric-coated naproxen and 20 mg non-enteric-coated 
esomeprazole magnesium, was used as a commercially available reference. The following 
enteric polymers were used: methacrylic acid – ethyl acrylate copolymer (1:1) Type A 
(Eudragit® L100-55, Evonik, Darmstadt, Germany), hydroxypropyl methylcellulose acetate 
succinate (HPMC-AS-LF, Aqoat® AS-LF, Shin-Etsu, Tokyo, Japan) and hydroxypropyl 
methylcellulose phthalate (HPMCP-HP-50, Shin-Etsu, Tokyo, Japan). Triethyl citrate (TEC, 
Sigma-aldrich, Bornem, Belgium) and talc (Luzenac® Pharma, Imerys Talc, Gent, Belgium) 
were used as excipients in the core formulation. The polymers used in the coat formulation 
were polyethylene oxide 100K (PEO 100K, Mw: 100000 g/mol, SentryTM Polyox® WSR N10, 
Colorcon, Dartford Kent, United Kingdom), polyvinylpyrrolidone (Kollidon®12 PF, Mw: 2500 
g/mol, BASF, Ludwigshafen, Germany), hydroxypropyl methylcellulose (Methocel® E3, 
viscosity: 3 mPa.s, Colorcon, Dartford Kent, United Kingdom), hydroxypropyl cellulose 
(Klucel® EF, Mw: 80000, Ashland, Covington, USA) and polyethylene glycol 4K (PEG 4K, Mw: 
4000 g/mol, Fagron, Waregem, Belgium). All other chemicals were of analytical grade. 
 
Hot-melt extrusion and co-extrusion 
 
In a first step hot-melt extrusion was performed to select an appropriate polymer matrix for 
core and coat separately, using a co-rotating Prism Eurolab 16 mm fully intermeshing twin 
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screw extruder (ThermoFisher Scientific, Karlsruhe, Germany) connected to a co-extrusion 
die having a core and coat insert with a diameter of 4 and 6 mm, respectively (Guill, West 
Warwick, USA). For the core formulations the processing temperatures are given in Table 1. 
 
Matrix polymer TEC 
conc.* 
Naproxen 
load 
Processing temperature(°C) 
(from feed opening to die-end) 
Appearance Degree of 
crystallinity 
Eudragit® L100-55 10 % 15 % 100/100/100/100/120/120/120 clear / 
HPMC-AS-LF 10 % 15 % 150/150/150/150/150/150/150 clear / 
HPMCP-HP-50 10 % 15 % 145/145/145/145/145/145/145 clear / 
Eudragit® L100-55 10 % 30 % 110/110/110/110/125/125/125 clear 1.3 % 
100/100/100/100/110/110/110 opaque 37.3 % 
HPMC-AS-LF 10 % 30 % 120/120/120/120/120/120/120 clear 2.6 % 
100/100/100/100/100/100/100 opaque 29.0 % 
HPMCP-HP-50 10 % 30 % 130/130/130/130/130/130/130 clear 0.7 % 
115/115/115/115/115/115/115 opaque spots 1.5 % 
HPMC-AS-LF / 50 % 120/120/120/110/110/100/100 opaque 70.8 % 
*The concentration of plasticizer is expressed in relation to the matrix polymer 
Table 1. Extrusion temperature, degree of crystallinity and extrudate appearance of 15, 30 and 50 % naproxen-
loaded core extrudates, with different matrices. 
 
The coat formulation was processed at a temperature of 100 °C in all zones of the extruder 
and the die. Premixes of drug, polymer and additives were fed into the extruder using a 
Brabender Flexwall® loss-in-weight powder feeder (Brabender, Duisburg, Germany) at a feed 
rate of 375 g/h for the coat and 300 g/h for the core material. A screw speed of 120 rpm was 
used for each of the extruders. 
In a second phase co-extrusion was carried out using two co-rotating Prism Eurolab 16 mm 
twin screw extruders (ThermoFisher Scientific, Karlsruhe, Germany), both connected to the 
co-extrusion die (Guill, West Warwick, USA). A cylindrical co-extrudate with a core diameter 
of 4 mm and a concentric coat with a thickness of 1 mm (total co-extrudate diameter: 6 mm) 
was manufactured. After cooling to room temperature the cylindrical co-extrudate was 
manually cut into cylinders of 10 mm length, which were used for further analysis. 
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In vitro drug release 
 
In vitro dissolution was performed using United States Pharmacopeia (USP) dissolution 
apparatus 2 (paddles) on an Evolution 6300 dissolution system (Distek, New Brunswick, New 
Jersey, USA), coupled with an Evolution 4300 automatic dissolution sampler (Distek, New 
Brunswick, New Jersey, USA). The temperature of the dissolution medium was kept at 37 ± 
0.5 °C and the rotational speed of the paddles was set to 100 rpm. To characterize the 
release of naproxen 750 ml of a 0.1 N solution of HCl was used as the dissolution medium for 
the first 2 h. After collecting the 2 h sample, 250 ml Na3PO4.12H2O 0.2 M was added to the 
dissolution vessel to adjust the pH of the medium to 6.8. Samples (filtered using Distek 45 
µm filters) of 5 ml were withdrawn after 0.5, 1, 1.5 and 2 h in the acid stage and 
consequently after 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h and 10 h in the pH 6.8 buffer 
stage. To assess the esomeprazole magnesium release a dissolution test in demineralized 
water was performed for 2 h. For this in vitro dissolution test samples of 5 ml were 
withdrawn after 5, 10, 15, 20, 30, 45, 60, 90 and 120 min. Each experiment was performed in 
triplicate. 
 
Ultra high performance liquid chromatography analysis 
 
For the determination of both active compounds in the dissolution samples an ultra high 
performance liquid chromatography (UHPLC) analysis was performed using a reversed-phase 
C18 column with a gradient system (10 min) based on aqueous 10 mM ammonium acetate 
(A) and acetonitrile (B). The gradient used was: a linear ramp from 0 to 5 min going from 85 
% A + 15 % B to 50 % A + 50 % B, changing over to 5 % A + 95 % B at 5.1 min, maintained for 
1.8 min and afterwards changing over to chromatographic start conditions 85 % A + 15 % B 
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from 6.9 min to 7 min, followed by an equilibration of 3 min preceding the next injection. An 
Acquity CSH C18 column (1.7 µm particle size, 2.1 x 100 mm) (Waters, Brussels, Belgium) was 
used in an oven set at 40 °C. The flow rate was set at 0.35 ml/min, injection volume was 0.3 
µl. A photo-diode array detector (Acquity, Waters, Brussels, Belgium) was used. For the 
quantification of esomeprazole magnesium a detection wavelength of 290 nm was used, 
whereas for naproxen the detection wavelength was set at 260 nm. An appropriate 
calibration curve was applied for quantification of esomeprazole magnesium and naproxen, 
respectively.  
For the quantification and purity determination of esomeprazole magnesium in the solid 
dosage forms a verified UHPLC method was developed, using an Acquity CSH C18 column 
(1.7 µm particle size, 2.1 x 100 mm) (Waters, Brussels, Belgium) in an oven set at 40 °C, with 
a gradient system (30 min) based on the same two-component mobile phase system: 
aqueous 10 mM ammonium acetate (A) and acetonitrile (B). The gradient used here was: a 
linear ramp from 2 to 20 min going from 90 % A + 10 % B to 5 % A + 95 % B, holding this 
condition for 5 min and afterwards changing over to chromatographic start conditions 90 % 
A + 10 % B from 25 to 25.1 min, maintaining this condition for 4.9 min as an equilibration 
step preceding a next injection. The flow rate was set at 0.35 ml/min, an injection volume of 
1.2 µl was used. For the quantification of esomeprazole magnesium a photo-diode array 
detector (Acquity, Waters, Brussels, Belgium), with a detection wavelength set at 301 nm, 
was used. Sample preparation was performed by stirring the extrudates in a 10 ml flask filled 
with demineralized water : acetonitrile in a 1:1 ratio. An appropriate calibration curve was 
applied for quantification of esomeprazole magnesium.  
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The UHPLC system consisted of an isocratic solvent pump, an automatic autosampler and a 
column oven (Acquity, Waters, Brussels, Belgium). Peak integration and data acquisition was 
performed using the software package Empower® (Waters, Brussels, Belgium). 
 
Modulated differential scanning calorimetry  
 
The crystallinity of naproxen in the enteric core matrix and the thermal behavior of pure 
compounds, physical mixtures and corresponding extrudates were studied using a 
differential scanning calorimeter Q2000 V24.8 equipped with a refrigerated cooling system 
(RCS) (TA Instruments, Leatherhead, UK). Nitrogen was used as purge gas through the DSC 
cell (50 ml/min) and the RCS unit (300 ml/min). Samples (± 8 mg) were run in hermetically 
closed Tzero pans with perforated lid, supplied by TA Instruments, with an underlying 
heating rate of 2 °C/min. The modulation period and amplitude were set at 60 s and 0.318 
°C, respectively. After a first heating cycle to 175 °C, samples were cooled to -30 °C using a 
linear cooling rate of 10 °C/min. Finally, a second modulated heating cycle was applied. Mass 
of sample pan and empty reference pan were taken into account. Temperature and enthalpy 
calibration were performed using an indium standard, whereas calibration of the heat 
capacity was performed using a sapphire standard. Modulated differential scanning 
calorimetry (MDSC) data were analyzed using the TA Instruments Universal Analysis 2000 
V4.7A software. Melting enthalpies and glass transition temperatures were determined in 
the total heat flow and reversing heat flow signal, respectively. Reported glass transition 
temperatures of the physical mixtures were determined in the second heating cycle to 
ensure maximal interaction between the compounds and to simulate a thermal history 
comparable to the extrudates when analyzed during the first heating cycle in MDSC. The 
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degree of crystallinity was calculated comparing the melting enthalpy of the naproxen 
melting peak in the analyzed sample to that of pure naproxen (147.2 J/g). 
 
X-ray diffraction  
 
Crystallinity was analyzed using X-ray diffraction (XRD) on pure compounds, physical 
mixtures and corresponding extrudates. X-ray diffraction was performed on a D5000 
diffractometer with Cu Kα radiation (λ = 1.54 Å) (Siemens, Karlsruhe, Germany) and a voltage 
of 40 mV in the angular range (2θ) varying from 4 to 60 ° using a step scan mode with a step 
size of 0.02 ° and a measuring time of 1 s/step. 
 
Attenuated total reflection Fourier-transform infrared analysis 
 
Attenuated total reflection Fourier-transform infrared (ATR FT-IR) spectroscopy was 
performed on the pure substances, physical mixtures and extrudates to identify molecular 
interactions formed between naproxen and the enteric polymers during extrusion. Spectra 
were recorded in absorbance mode using a Nicolet iS5 ATR FT-IR spectrometer 
(ThermoFisher Scientific, Karlsruhe, Germany). A diamond ATR crystal was pressed against 
the samples in order to obtain the ATR FT-IR spectra in the 4000 – 550 cm-1 range, with a 
resolution of 4 cm-1, averaged over 32 scans. 
 
Stability study 
 
Clear core extrudates formulated with different polymer matrices and 30 % naproxen (Table 
1), and core extrudates containing 50 % naproxen and 50 % HPMC-AS-LF were manufactured 
to perform a stability study. Immediately after extrusion, the formulations were filled in an 
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amber glass container and stored in closed condition at 25 °C/60 %RH and in open and 
closed condition at 40 °C/75 %RH. To investigate the influence of storage MDSC, XRD, and in 
vitro drug release tests were performed on the extrudates immediately after manufacturing 
(T0), after 1 week (T1w), 2 weeks (T2w), 1 month (T1m) or 6 weeks (T6w), 3 months (T3m) 
and 6 months (T6m) storage. 
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RESULTS AND DISCUSSION 
 
In order to formulate a core/coat fixed-dose combination product via co-extrusion both 
layers were first independently developed. Afterwards the compatibility of the core and coat 
matrices was checked. Finally it was evaluated if the final drug-loaded formulations were 
compatible and if a fixed-dose combination product with the desired release characteristics 
could be manufactured via co-extrusion. 
 
Core formulation 
 
To develop a core matrix formulation providing enteric protection for naproxen, using hot-
melt extrusion (HME) as production technology, three enteric polymers were compared: 
methacrylic acid - ethylacrylate copolymer (Eudragit® L100-55), hypromellose acetate 
succinate (HPMC-AS-LF) and hypromellose phthalate (HPMCP-HP-50). Hot-melt extrusion of 
these polymers in combination with 15 % naproxen required a plasticizer as without 
plasticizer the torque values during extrusion were too high. Although naproxen (with a 
melting point at 156.1 °C and a glass transition temperature (Tg) of 6.2 °C [10]) had a 
concentration-dependent plasticizing effect on these polymers (Table 2), the effect of this 
polymer/drug interaction on the process temperature and/or torque during extrusion 
cannot be exploited to its full extent as the plasticizing effect was only evident during the 
second heating cycle of the MDSC analysis of a physical mixture. Hence, these drug/polymer 
interactions were only established after intense intermolecular contact following the 1st 
heating phase of the MDSC experiment.  
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Formulation Tg (° C) 
 Eudragit®L100-55 + 10%TEC HPMC-AS-LF + 10%TEC HPMCP-HP-50 + 10%TEC 
100% matrix 90.2 91.1 95.7 
85% matrix + 
15% naproxen 
61.4 63.4 59.0 
70% matrix + 
30% naproxen 
24.9 24.2 26.9 
 
Table 2. Glass transition temperatures (Tg) of placebo and drug-loaded (15 and 30 %) physical mixtures 
measured by MDSC in a 2
nd
 heating cycle. 
 
TEC was an efficient plasticizer for Eudragit® L100-55, reducing its Tg from 117.7 °C to 108.5 
and 90.2 °C after the 1st and 2nd heating cycle, respectively, at a concentration of 10 % TEC. 
For this formulation a screw speed of 120 rpm and a higher processing temperature at the 
die-end of the barrel was required to reduce die swell. The addition of 10 % talc to the 
formulation was critical as it improved the flow properties of the powder, ensuring 
consistent feeding of the powder into the extruder. When 10 % TEC was added to HPMC-AS-
LF the Tg lowered from 122.8 °C to 97.5 and 91.1 °C after the 1st and 2nd heating cycle 
respectively. This formulation, containing 15 % naproxen, yielded an extrudate with a 
smooth appearance and without die swell when processed at 150 °C. The addition of 10 % 
TEC to HPMCP-HP-50 as enteric polymer reduced Tg from 142.1 °C to 126.6 and 95.7 °C after 
the 1st and 2nd heating cycle, respectively. The 15 % drug-loaded formulation yielded 
extrudates that were processable at 145 °C, but had an irregular surface.  
At a 15 % naproxen content hot-melt extrusion of all polymer formulations resulted in clear 
extrudates with the entire drug content molecularly dispersed in the polymer matrix. A 
higher drug load (30 %) resulted in opaque formulations with a significant degree of 
crystallinity. However, the extrusion temperature was critical to the physicochemical state of 
the drug in the extrudates as nearly the entire naproxen content was molecularly dispersed 
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in the polymer matrices when processed at a higher temperature (Table 1), e.g. HPMC-AS-LF 
mixtures with 30 % drug processed at 100 and 120 °C contained 29.0 and 2.6 % crystalline 
drug, respectively. This was also reflected in the X-ray diffractogram of the Eudragit® L100-
55 extrudates processed at different extrusion temperatures (Fig. 1). 
 
 
Figure 1. X-ray diffraction patterns of (from bottom to top): naproxen (A), Eudragit® L100-55 (B), the 
formulation containing 30 % naproxen in a 70 % (Eudragit® L100-55 : TEC 9:1) matrix, processed at, from feed 
opening to die-end, 110/110/110/110/125/125/125 °C (C) and 100/100/100/100/110/110/110 °C (D). 
 
Interestingly the hypromellose-based polymers containing a higher naproxen content could 
be extruded at a lower temperature, even when they contained a significant crystalline drug 
fraction. This can be linked to the plasticizing effect of naproxen on these polymers: thermal 
processing of mixtures with a higher drug content induced more interaction between drug 
and polymer in the extrusion barrel. Hence, a lower extrusion temperature could be 
employed, without risking too high torque values. This plasticizing effect of naproxen was 
even more evident for a HPMC-AS-LF formulation containing 50 % naproxen which could be 
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processed without plasticizer at an extrusion temperature of 
120/120/120/110/110/100/100 °C from feed opening to die-end, despite its high percentage 
of crystalline drug. 
The in-vitro naproxen release profiles of the different polymer formulations containing 10 % 
TEC as a plasticizer and loaded with 15 % naproxen are shown in Fig. 2. For all formulations 
naproxen release in 0.1 N HCl was prevented for 2 h. In pH 6.8 buffer HPMCP-HP-50 matrices 
showed a faster release rate compared to HPMC-AS-LF and Eudragit® L100-55 formulations. 
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Figure 2. In-vitro naproxen release profile of formulations containing 15 % naproxen and an enteric polymer, 
plasticized with 10 % TEC: Eudragit® L100-55 (●), HPMC-AS-LF (■), HPMCP-HP-50 (▲). Dissolution in 0.1 N HCl 
(2 h) and pH 6.8 buffer (10 h) at 37 °C using paddle dissolution system at 100 rpm (Mean ± SD; n=3). 
 
Although the process temperature did affect the API’s physicochemical state for the 30 % 
naproxen formulations, it did not have a significant effect on the release profiles. The enteric 
protection of naproxen during a 2 h period was not impaired in formulations containing 30 
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and 50 % drug. However, naproxen release in pH 6.8 buffer was determined by drug 
concentration: after 2 h HPMC-AS-LF matrices containing 30 and 50 % naproxen released 58 
and 81 % of their drug content, respectively (Fig. 3). 
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Figure 3. In-vitro naproxen release profile of two extruded HPMC-AS-LF formulations with 30 (●) and 50 (■) % 
drug load. Dissolution in 0.1 N HCl (2 h) and pH 6.8 buffer (10 h) at 37 °C using paddle dissolution system at 100 
rpm (Mean ± SD; n=3). 
 
 
A stability study was performed on the transparent extrudates containing 30 % naproxen 
and 10 % TEC. Independent of the matrix polymer, naproxen completely recrystallized after 
two weeks storage at 40 °C/75 %RH, while XRD analysis detected no recrystallization over a 
6 month period in a hypromellose matrix stored at 25 °C/60 %RH. For the 50 % naproxen 
formulation in HPMC-AS-LF the physicochemical state nor the dissolution profiles of the drug 
had changed after 6 months storage at the different storage conditions.  
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To identify intermolecular interactions between naproxen and polymer (Eudragit® L100-55, 
HPMC-AS-LF), Fourier-transform infrared (FT-IR) spectra were collected of transparent 
extrudates, containing 30 % drug and plasticized with 10 % TEC, immediately after 
manufacturing and after 2 weeks storage at 40 °C/75 %RH in open condition (i.e. after 
recrystallization of the drug). From the FT-IR spectra of the Eudragit® L100-55 formulation 
shown in Fig. 4 and Fig. 5 it is suggested that naproxen is mainly molecularly dispersed in the 
formulation immediately after processing, since some of the peaks characteristic for 
naproxen completely disappeared, e.g. peaks at 1347 cm-1 (rocking of OH of the carboxyl 
group [11]) and 642 cm-1 (wagging of OH of the carboxyl group [11]), while others 
broadened, e.g. peaks at 1416 cm-1 (in-plane bending of CH of the naphthalene ring [11]) and 
1628 cm-1 (bond stretching of the naphthalene ring [11]), confirming the loss of crystalline 
material (1.3 %).  
 
 
Figure 4. ATR FT-IR spectra of naproxen (blue), Eudragit® L100-55 (green), physical mixture of Eudragit® L100-
55 plasticized with 10 % TEC and a drug load of 30 % naproxen (red) and the extrudate of the same formulation 
immediately after processing (yellow). 
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Figure 5. ATR FT-IR spectra of naproxen (blue), physical mixture of Eudragit® L100-55 plasticized with 10 % TEC 
and a drug load of 30 % naproxen (red) and the extrudate of the same formulation immediately after 
processing (yellow) and after storage for 2 weeks at 40°C/75%RH (grey). 
 
After storage for 2 weeks at 40 °C/75 %RH the visual recrystallization in the extrudate was 
confirmed by the appearance of characteristic naproxen peaks in the FT-IR spectra (Fig. 5). 
The changing ratio between the peaks at 1727 cm-1 and 1686 cm-1 (attributed to non-
hydrogen and hydrogen bonded –C=O stretching of the crystal structure [12]) before and 
after storage implied that the amount of hydrogen bonds formed during processing between 
the drug and the matrix decreased over time (Fig. 6). While the interaction between drug 
and polymer is maximal immediately after processing, the reduction of the peak at 1686   
cm-1 after storage clearly indicated that the amount of hydrogen bonds decreased. The peak 
shifts observed in the extrudates for the naproxen peaks at 1227 cm-1 (stretching of CO of 
the methoxy group [11]) and 1603 cm-1 (bond stretching of the naphthalene ring [11]) are 
another indication of the hydrogen bond interaction between drug and matrix (Fig. 4). 
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Figure 6. ATR FT-IR spectra of naproxen (blue), physical mixture of Eudragit® L100-55 plasticized with 10 % TEC 
and a drug load of 30 % naproxen (red), the extrudate of the same formulation immediately after processing 
(yellow) and after storage for 2 weeks at 40°C/75 %RH (grey). 
 
 
Also the HPMC-AS-LF formulations showed a partial recrystallization over time. The 
characteristic naproxen peaks were more pronounced in the FT-IR spectra of the extrudates 
after storage. Moreover after storage the characteristic naproxen peaks in the FT-IR spectra 
of the extrudate were not different from those of pure naproxen (Fig. 7). Also at 1727 and 
1686 cm-1 (Fig. 8) the FT-IR spectrum of the stored extrudate has the same profile as pure 
drug. This indicated that there is no permanent interaction between HPMC-AS-LF and 
naproxen. 
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Figure 7. ATR FT-IR spectra of naproxen (blue), HPMC-AS-LF (green), the physical mixture of HPMC-AS-LF 
plasticized with 10 % TEC and a drug load of 30% naproxen (red), the extrudate of the same formulation 
immediately after processing (yellow) and after storage for 2 weeks at 40°C/75%RH (grey). 
 
 
Figure 8. ATR FT-IR spectra of naproxen (blue), physical mixture of HPMC-AS-LF plasticized with 10 % TEC and a 
drug load of 30 % naproxen (red), the extrudate of the same formulation immediately after processing (yellow) 
and after storage for 2 weeks at 40°C/75%RH (grey). 
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Coat formulation 
 
Formulation of esomeprazole magnesium presents a challenge since degradation of the drug 
can occur due to a high process temperature and in acidic environment [13]. When 
formulating esomeprazole magnesium in the enteric polymers Eudragit® L100-55, HPMC-AS-
LF and HPMCP-HP-50 complete degradation of the drug occurred, most likely due to the 
presence of acidic groups in the polymers. Therefore esomeprazole magnesium was 
formulated in an immediate release polymer, separated from the naproxen-containing 
enteric layer. A similar approach was used in a commercially available combination product 
of naproxen and esomeprazole magnesium (Vimovo®) which is formulated as an enteric-
coated naproxen tablet with a non-enteric-coated esomeprazole magnesium layer on top 
(both layers are physically separated via a barrier coat). The immediate release polymers 
tested were PEO 100K, Kollidon®12 PF, Klucel® EF and Methocel® E3. While extrusion of the 
PEO 100K formulation was feasible at a process temperature of 100 °C, the other polymers 
required a processing temperature of 130 °C, even with the addition of a plasticizer, and as a 
result more esomeprazole magnesium degradation occurred: only 40 to 75 % of the drug 
content was recovered after extrusion, vs. 94 % drug recovery in the PEO 100K formulation. 
As drug release from the PEO 100K polymer was limited to 70 % after 45 min, PEG 4K was 
added to the mixtures: complete drug release was observed after 45 min in combination 
with smooth processing (lower torque) for a 2 % esomeprazole magnesium loaded PEO 100K 
: PEG 4K (1:1) formulation (Fig. 9).  
 
CHAPTER 4 – ENTERIC PROTECTION OF NAPROXEN IN A FIXED-DOSE COMBINATION PRODUCT PRODUCED BY 
HOT-MELT CO-EXTRUSION 
150 
 
0 30 60 90 120
0
20
40
60
80
100
Time (min)
%
 C
u
m
u
la
ti
v
e
E
s
o
m
e
p
ra
z
o
le
 M
g
 r
e
le
a
s
e
Figure 9. In-vitro esomeprazole Mg release from the coat extrudate containing 2 % esomeprazole Mg 
formulated in PEO 100K : PEG 4K 1:1 (▲) and pure esomeprazole Mg powder (●). Dissolution in demineralized 
water for 2 h at 37 °C using paddle dissolution system at 100 rpm (Mean ± SD; n=3). 
 
Thermal analysis of the physical mixture and the extruded formulation only revealed a 
melting endotherm of PEO 100K and PEG 4K, due to dissolution of the esomeprazole 
magnesium crystals in molten polymer. While two distinct melting endotherms were 
detected for the physical mixture, only a single endotherm was visible in the extruded 
sample, indicating the formation of a single phase system. 
 
Co-extrudate formulation 
 
After evaluating the naproxen-containing enteric layer and the esomeprazole magnesium-
containing immediate release layer separately, co-extrusion of 50 % naproxen in the HPMC-
AS-LF core and 2 % esomeprazole magnesium in the PEO 100K : PEG 4K 1:1 coat yielded an 
opaque co-extrudate with a smooth surface. However, after cooling of the co-extrudate 
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discoloration was observed at the interface of core and coat (Fig. 10), and in vitro dissolution 
revealed that only 72 % of the esomeprazole magnesium content could be recovered, 
despite the fast and complete dissolution of the PEO/PEG layer.  
 
 
Figure 10. Top view and detail of separated core and coat layer from final co-extrudate, containing 50 % 
naproxen in the HPMC-AS-LF core and 2 % esomeprazole magnesium in the PEO 100K : PEG 4K 1:1 coat, 
showing a discoloration at the core surface. 
 
 
 
Since this was not seen when processing the co-extrudate with a placebo HPMC-AS-LF + 10 
% TEC core, the discoloration is most probably due to an interaction between the naproxen 
fraction at the core surface and esomeprazole magnesium in the coat, leading to 
degradation of the acid-labile esomeprazole magnesium. A possible solution to this problem 
could be the extrusion of a barrier layer between core and coat. This technique is already 
applied for the production of multilayer films in packaging applications [14, 15], but could 
not be evaluated at this stage as it implies the use of a third extruder. 
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CONCLUSION 
 
Hot-melt extrusion was a suitable technique to manufacture an enteric 50 % naproxen- 
loaded dosage form. Producing a fixed-dose combination product also containing 
esomeprazole magnesium in a separate immediate releasing coat was not an adequate 
solution to prevent interaction between both chemically incompatible API’s. Co-extrusion as 
a continuous one-step manufacturing process for the production of a fixed-dose 
combination product providing enteric release to naproxen and immediate release to 
esomeprazole magnesium only would be feasible when a third layer of polymer, separating 
the naproxen-loaded enteric formulation in the core from the coat, would be applied to 
prevent interaction between both API’s.  
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GENERAL CONCLUSIONS  
AND FUTURE PERSPECTIVES 
 
 
The overall aim of this work was to evaluate the possibilities of hot-melt co-extrusion for the 
production of multilayer oral dosage forms, providing different release profiles for each of 
the drugs incorporated in the core and coat of the co-extruded form. 
 
Hot-melt co-extrusion was a suitable technique to manufacture mini-matrices with a 
sustained release metoprolol tartrate-loaded core and an immediate release 
hydrochlorothiazide-loaded coat. The in vitro metoprolol tartrate release from the core 
could be sustained over a longer period by lowering the concentration of polyethylene oxide 
(added as a hydrophilic additive to the plasticized ethylcellulose matrix) or by reducing the 
drug load. The core formulations were successfully combined via co-extrusion with a 
polyethylene oxide/polyethylene glycol-based coat which provided immediate release of 
hydrochlorothiazide. The high metoprolol tartrate plasma concentrations detected after oral 
administration to dogs allowed to reduce the administered dose. In addition, a mathematical 
model considering the controlled release of metoprolol tartrate from the dosage form and 
its fate in vivo allowed to predict the in vivo drug plasma profiles. 
 
Calendering was identified as a downstream processing technique to produce tablet-shaped 
fixed-dose combination products with an immediate release hydrochlorothiazide-loaded 
coat and a sustained release metoprolol tartrate-loaded core. The metoprolol tartrate 
GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
156 
 
release from the core of the calendered tablet was significantly prolonged in comparison to 
a multiparticulate dosage form, prepared via manual cutting of the co-extrudates into mini-
matrices, due to longer diffusion path length. The physicochemical properties of both drugs 
were not affected by the calendering procedure. 
 
Furthermore, a bilayer dosage form which provided sustained release of 2 anti-diabetic 
drugs was successfully developed via co-extrusion, by incorporating metformin HCl and 
gliclazide in the core and coat layer, respectively. At least 30 % polycaprolactone was 
required in the coat layer to adequately sustain the release of the freely soluble metformin 
HCl from a polycaprolactone core containing 70 % drug. The addition of Kollidon® VA 64 to 
the polycaprolactone-based coat was essential to ensure complete release of gliclazide over 
24 h as the Kollidon® VA 64 phase solubilized the drug in the coat layer. 
 
The final part of this study identified the potential of continuous hot-melt extrusion for the 
manufacturing of matrix formulations which provided enteric protection to naproxen, using 
several polymers (Eudragit® L100-55, HPMC-AS-LF and HPMCP-HP-50). These enteric 
polymer matrices (loaded with naproxen) could be easily processed via co-extrusion in 
combination with a polyethylene oxide/polyethylene glycol matrix containing esomeprazole 
magnesium. This co-extruded dosage forms ensured complete release of esomeprazole 
magnesium within 45 min. However, to prevent interaction between both API’s (naproxen 
and esomeprazole magnesium) at the interface of the core and coat layer a buffering layer 
between coat and core is required.  
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Overall, this research project illustrated that hot-melt co-extrusion offers several possibilities 
for the continuous production of fixed-dose combination products, providing an adequate 
release profile for each of the drugs incorporated. However, additional topics must be 
further explored in order to fully develop the possibilities of co-extrusion for the production 
of oral fixed-dose combination dosage forms and to implement this technique in 
pharmaceutical industry: 
-  The downstream process and its effect on product quality should further be 
investigated to increase the possibilities for in-line shaping or cutting of the co-
extrudate. Since most downstream applications require cooling of the melt, the 
effect of cooling rate on the quality of the extrudate must be elaborated. Next to 
altering the physicochemical state of the drug, cooling will also change the viscosity 
of the extrudate, which is particularly relevant for downstream processing.  
-  New types of polymers, currently not used for oral pharmaceutical applications, 
should be evaluated for co-extrusion of oral solid dosage forms as there is a growing 
need for novel polymers, enabling the formulation of combination products via hot-
melt co-extrusion. Not only should the materials be thermoplastic and sufficiently 
deformable after softening, specific characteristics which enable co-extrusion could 
be also built into the matrix. New tailor-made sets of polymers should be explored in 
hot-melt co-extrusion. In this way melt viscosity and processing conditions of the 
different layers could be matched, adequate adhesion between layers could be 
ensured and specific release characteristics could be achieved. 
-  An extension of co-extrusion to three- or multilayered co-extrudates would be a 
logical next step for this innovative technology as this would open new opportunities, 
e.g. an additional buffering layer could prevent interactions at the interface between 
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layers, coupling more extruders could allow to combine even more than 2 API’s in 
differently formulated layers.  
-  For the implementation of a fully equipped hot-melt co-extrusion line for the 
continuous production of pharmaceutical dosage forms some technical challenges 
can be identified as this technique is relatively new to the pharmaceutical industry. 
Some examples of possible improvements are: (a) the incorporation of a robust and 
accurate system to add a liquid excipient - e.g. plasticizer -  to the melt in the 
extruder; (b) the design of different final product shapes for pharmaceutical fixed-
dose combination products; (c) the development of specific downstream equipment 
allowing in-line shaping or cutting of a co-extrudate without affecting the drug ratio 
in both layers; (d) the incorporation of PAT in the co-extrusion line, monitoring the 
properties of the melt, controlling the process settings and measuring the critical 
quality attributes of the final product. 
-  Since full-scale manufacturing requires a high throughput rate of materials upscaling 
from lab-scale extruders to production-scale equipment is an essential aspect for 
successful introduction of this technique in the pharmaceutical industry. 
Compensating the impact of upscaling on the flow of the layers through the co-
extrusion die and handling the pressure generated in the die would be critical in 
order to maintain the fixed dimensions of the co-extruded dosage form. To ensure a 
smooth transition a thorough evaluation of equipment- and process-related 
parameters and of critical-to-quality attributes would be a first step.  
-  With respect to the analytical challenges related to fixed-dose combination products 
extensive compatibility and stability studies would be needed in function of the 
combination of active pharmaceutical ingredients.  
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-  Additional applications of fixed-dose combination products could be designed by 
combining co-extrusion with other techniques, e.g. integration of co-extrusion with 
injection molding could result in the next generation of manufacturing technology for 
shaping co-extrudates into their final dosage form. 
-   Combining co-extrusion with other formulation techniques could be promising to 
tackle specific formulation issues. As hot-melt extrusion can be used for a number of 
specific applications (e.g. enhancing the solubility of poorly soluble drug compounds, 
in-situ co-crystal formation, avoiding of particle aggregation, morphological instability 
and poor wettability via nanoparticle engineering), combining these solutions with 
co-extrusion can open new perspectives for the formulation of new drug 
combinations in the increasing market of fixed-dose combination dosage forms. 
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SUMMARY 
 
 
In this thesis hot-melt co-extrusion was explored as a manufacturing technique for the 
production of multilayer pharmaceutical oral dosage forms. Given the increasing importance 
of fixed-dose combination products in numerous therapeutic fields this innovative 
continuous manufacturing technology brings significant added value, since the most 
appropriate matrix can be selected for each of the different drugs incorporated. In this way 
fixed-dose combination products with enhanced release characteristics can be produced.  
 
In the Introduction hot-melt co-extrusion (an innovative technology for the production of 
pharmaceutical fixed-dose combination dosage forms) is discussed and an overview of the 
equipment needed for co-extrusion is provided. Because the geometrical design of the die 
dictates the shape of the final product, different die types are discussed. As shaping of the 
co-extruded formulation into its final form via a continuous process remains a major 
challenge, downstream processing of co-extrudates into drug products is discussed. 
Important requirements for material selection are pointed out and examples of medical and 
pharmaceutical applications are presented. The increasing importance of fixed-dose 
combination products is emphasized, given their therapeutic advantages and major 
contributions to life cycle management. In addition to the benefits of the technique also 
some barriers to the implementation of co-extrusion in the pharmaceutical industry are 
discussed.  
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The successful development via hot-melt co-extrusion of fixed-dose mini-matrices with a 
core offering a range of controlled release profiles and an immediate release coat was 
demonstrated in Chapter 1. The in vitro metoprolol tartrate release from the core was 
substantially sustained by lowering the concentration of polyethylene oxide (added as a 
hydrophilic additive to the plasticized ethylcellulose matrix) or by reducing the drug load. 
The in vitro release of hydrochlorothiazide from the polyethylene oxide/polyethylene glycol 
coat was completed within 45 min for all formulations. Tensile testing of the core/coat mini-
matrices revealed an adequate adhesion between both layers. Raman mapping showed that 
no migration of active substances occurred between core and coat. Physicochemical state 
characterization indicated that the crystalline state of metoprolol tartrate was not affected 
by thermal processing via hot-melt extrusion, while hydrochlorothiazide was dissolved in the 
coat. These physicochemical characteristics were maintained during the stability study. 
Considering the bioavailability of metoprolol tartrate after oral administration to dogs, the 
different co-extruded formulations offered a range of sustained release profiles. Moreover, 
high metoprolol tartrate plasma concentrations were reached in dogs, which allowed to 
reduce the administered dose. Interestingly, the resulting metoprolol tartrate plasma 
concentrations could be predicted using an appropriate mathematical model, based on the 
observed in vitro release kinetics and the in vivo fate of metoprolol tartrate. The theoretical 
predictions agreed well with the independent experimental results, implying the number of 
in vivo studies required for product optimisation can be reduced. 
 
In Chapter 2 calendering was evaluated as a downstream processing step to continuously 
produce tablet-shaped fixed-dose combination products from multilayered matrix co-
extrudates. Cylindrical co-extrudates with a metoprolol tartrate-loaded sustained-release 
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core and a hydrochlorothiazide-loaded immediate-release coat were shaped in-line via 
calendering, using chilled rolls with tablet-shaped cavities. In vitro metoprolol tartrate 
release from the ethylcellulose core of the calendered tablets was sustained over 24 to 48 h 
and was significantly prolonged in comparison to the sustained release of a multiparticulate 
dosage form, prepared by manual cutting of the co-extrudates into mini-matrices. Analysis 
of the dosage forms using X-ray micro-computed tomography only detected small 
differences between the pore structure of the core of the calendered tablet and the mini-
matrices. Differences in diffusion path length were the main contributing factor to changes 
in release kinetics in function of the post-processing technique. Terahertz pulsed imaging 
visualized that adhesion between the core and coat of the calendered tablet was not 
complete and a gradient in coat thickness (varying from 200 to 600 µm) was observed. 
Modulated differential scanning calorimetry and X-ray diffraction indicated that the 
physicochemical properties of both drugs were not affected by the calendering procedure. 
 
In Chapter 3 bilayer dosage forms containing an anti-diabetic drug in both core and coat 
were successfully developed by co-extrusion, offering a fixed-dose combination product 
sustaining the release over 24 h for both metformin HCl and gliclazide. From this study it was 
clear that co-extrusion of a coat layer, containing at least 30 % CAPA® 6506 as a hydrophobic 
polymer, was necessary to adequately sustain the release of the highly dosed freely soluble 
drug from the CAPA® 6506 core containing 70 % drug. Inclusion of Kollidon® VA 64 in the 
coat ensured complete release over 24 h of gliclazide via solubilization of the drug in the 
Kollidon® VA 64 phase. 
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In Chapter 4 co-extrusion was evaluated as a manufacturing technique to produce a fixed-
dose combination product providing enteric protection to naproxen and immediate release 
to esomeprazole magnesium. The plasticizing effect of naproxen and triethyl citrate (TEC) 
was tested on the enteric polymers investigated (Eudragit® L100-55, HPMC-AS-LF and 
HPMCP-HP-50). Core matrix formulations containing HPMC-AS-LF, TEC and a naproxen load 
of 15, 30 and 50 % were processed and characterized. In vitro naproxen release in 0.1 N HCl 
was prevented during 2 h for all formulations. Hot-melt extrusion was a suitable technique 
to manufacture an enteric 50 % naproxen-loaded dosage form. When esomeprazole 
magnesium was formulated in a polyethylene oxide 100K : polyethylene glycol 4K (1:1) 
matrix, the formulation could be easily processed and complete in vitro drug release was 
observed after 45 min. A fixed-dose combination product which contained esomeprazole 
magnesium in the immediate release coat and naproxen in the core was not an adequate 
solution for the chemical incompatibility between both API’s as drug interaction occurred at 
the interface of both layers. Hence co-extrusion as a one-step manufacturing process of a 
fixed-dose combination product providing enteric release to naproxen and immediate 
release to esomeprazole magnesium would only be feasible when an intermediate polymer 
layer is applied to separate the naproxen-containing enteric core formulation from the 
esomeprazole magnesium-containing coat. 
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SAMENVATTING 
 
 
In deze doctoraatsthesis werd het gebruik van ‘hot-melt’ co-extrusie onderzocht als 
productietechniek voor farmaceutische orale toedieningsvormen. Door het toenemende 
belang van combinatiepreparaten in verschillende therapeutische domeinen levert deze 
innovatieve en continue technologie een belangrijke toegevoegde waarde. Door de meest 
geschikte drager te selecteren voor elk van de lagen kunnen combinatiepreparaten met 
optimale vrijstellingseigenschappen voor elk geneesmiddel aangemaakt worden. 
 
Eerst wordt een introductie tot ‘hot-melt’ extrusie en een overzicht van de benodigde 
uitrusting gegeven. Omdat het ontwerp van de matrijs de vorm van het eindproduct bepaalt, 
worden verschillende matrijstypes besproken. Een belangrijke uitdaging blijft om het co-
extrudaat in een finale toedieningsvorm aan te maken via een continu proces. Hiervoor 
wordt een overzicht gegeven van diverse oplossingen. Belangrijke vereisten voor 
materiaalselectie alsook voorbeelden van medische en farmaceutische toepassingen worden 
beschreven. Aanvullend op de voordelen van de techniek worden ook enkele knelpunten 
voor de implementatie van co-extrusie in de farmaceutische industrie aangehaald. 
 
De succesvolle ontwikkeling van minimatrices via ‘hot-melt’ co-extrusie met een kern die 
mogelijkheden biedt voor verschillende vertraagde vrijstellingsprofielen en een mantel die 
zorgt voor snelle geneesmiddelvrijstelling wordt besproken in Hoofdstuk 1. De in vitro 
vrijstelling van metoprololtartraat uit de kern werd in belangrijke mate vertraagd door de 
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concentratie aan polyethyleenoxide, toegevoegd als hydrofiele component aan de matrix 
bestaande uit ethylcellulose en een weekmaker, te verlagen of door de 
geneesmiddelconcentratie te verminderen. De in vitro vrijstelling van hydrochloorthiazide 
uit de polyethyleenoxide/polyethyleenglycol mantel was binnen 45 minuten voltooid. 
Trektesten gaven aan dat er voldoende adhesie was tussen de kern en de mantel. Bovendien 
toonde Raman ‘mapping’ aan dat er geen migratie van de activa plaatsvond tussen de kern 
en de mantel. Vaste toestand karakterisatie wees uit dat de kristallijne toestand van 
metoprololtartraat behouden bleef tijdens ‘hot-melt’ extrusie, terwijl het 
hydrochloorthiazide opgelost was in de mantel. Deze fysicochemische karakteristieken 
werden bevestigd tijdens een stabiliteitsstudie. Na orale toediening van de verschillende co-
extrudaten aan honden werden voor de biologische beschikbaarheid van metoprololtartraat 
verschillende vertraagde vrijstellingsprofielen waargenomen. Meer nog, de hoge 
metoprololtartraat plasmaconcentratie die bereikt werd bij de hond, liet toe om de 
toegediende dosis te halveren. Gebruik makend van een gepast wiskundig model, opgesteld 
op basis van de waargenomen in vitro vrijstellingskinetiek en het in vivo 
plasmacurvetijdsprofiel, kon aangetoond worden dat de theoretische voorspellingen een 
hoge predictiegraad vertoonden. Hierdoor kan het aantal in vivo studies nodig voor 
productoptimalisatie gereduceerd worden.    
 
In Hoofdstuk 2 werd ‘calendering’, als verwerkingsstap om op continue wijze 
combinatiepreparaten in tabletvorm te produceren, geëvalueerd. Cilindrische co-extrudaten 
met metoprololtartraat en hydrochloorthiazide werden ‘in-line’ gevormd met behulp van 
een ‘calender’, waarbij gekoelde rollen met tabletvormige uitsparingen werden gebruikt. De 
in vitro metoprololtartraatvrijstelling uit de ethylcellulose kern van de met de ‘calender’ 
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gevormde tabletten werd vertraagd over een tijdsspanne van 24 tot 48 u, wat significant 
trager was dan de vertraagde vrijstelling die werd bekomen met de multiparticulaire 
toedieningsvormen. Bij analyse van de toedieningsvormen aan de hand van X-stralen micro-
CT werden enkel kleine verschillen in poriënstructuur gedetecteerd tussen de kern van het 
gevormde tablet en de minimatrices. De diffusielengte bleek het belangrijkste 
vrijstellingsmechanisme te zijn. Door middel van ‘terahertz pulsed imaging’ werd duidelijk 
dat de adhesie tussen kern en mantel niet volledig was en werd een diktegradiënt van de 
mantel (variërend tussen 200 en 600 µm) geobserveerd. Aan de hand van gemoduleerde 
differentiaal scanning calorimetrie en X-stralen diffractie werd aangetoond dat de 
fysicochemische eigenschappen van beide geneesmiddelen niet aangetast werden door het 
‘calenderen’. 
 
In Hoofdstuk 3 werd aan de hand van co-extrusie een monolithische toedieningsvorm 
ontwikkeld bestaande uit twee lagen, welke elk een anti-diabeticum bevatten. Het 
combinatiepreparaat vertoonde een vertraagde vrijstelling over 24 u voor zowel metformine 
HCl als gliclazide. Uit deze studie werd duidelijk dat co-extrusie van een mantel, met 
minstens 30 % CAPA® 6506 als hydrofoob polymeer, nodig was om de vrijstelling van het 
hoog gedoseerde goed wateroplosbare metformine HCl voldoende te vertragen. Het 
solubiliseren van gliclazide in de Kollidon® VA 64 fase van de mantel verzekerde de volledige 
vrijstelling van het geneesmiddel over 24 u. 
 
In Hoofdstuk 4 werd co-extrusie geëvalueerd als productietechniek voor het aanmaken van 
een combinatiepreparaat dat enterische bescherming biedt aan naproxen en een 
onmiddellijke vrijstelling aan esomeprazole magnesium. Het weekmakend effect van 
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naproxen en tri-ethyl citraat (TEC) op de onderzochte enterische polymeren (Eudragit® L100-
55, HPMC-AS-LF en HPMCP-HP-50) werd getest. Matrixformulaties voor de kern bestaande 
uit HPMC-AS-LF, TEC en een naproxen concentratie van 15, 30 of 50 % werden aangemaakt 
en gekarakteriseerd. De in vitro naproxen vrijstelling in 0.1 N HCl werd verhinderd 
gedurende 2 u voor alle formulaties. ‘Hot-melt’ extrusie bleek een geschikte techniek om 
een 50 % naproxen beladen toedieningsvorm aan te maken. Wanneer esomeprazole 
magnesium geformuleerd werd in een polyethyleenoxide 100K : polyethyleenglycol 4K (1:1) 
matrix, kon de formulatie makkelijk verwerkt worden en werd een volledige in vitro 
geneesmiddelvrijstelling waargenomen na 45 min. Een combinatiepreparaat aanmaken dat 
naast naproxen ook esomeprazole magnesium bevat in een afzonderlijke onmiddellijke 
vrijstellingsmantel bleek geen afdoende oplossing om interactie tussen de twee chemisch 
onverenigbare geneesmiddelen te vermijden. Co-extrusie als continu productieproces voor 
het aanmaken van een combinatiepreparaat dat enterische bescherming biedt aan naproxen 
en onmiddellijke vrijstelling van esomeprazole magnesium toelaat, zou enkel bruikbaar zijn 
wanneer een derde polymeerlaag de kern van de mantel afschermt. 
 
Er kan geconcludeerd worden dat ‘hot-melt’ co-extrusie, als continue productietechniek, 
talrijke mogelijkheden biedt voor het aanmaken van combinatiepreparaten voor oraal 
gebruik.  
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